In the last century, a virtual "knowledge explosion" has taken place with regard to women's health issues. In addition, there have been changes in the roles assumed by women in the home and in the workplace. Alterations and improvements in the pharmacologic and surgical treatment of many women's illnesses and health issues have also impacted outcomes and altered perspectives for long-term well-being and quality of life. For the dental healthcare professional, an expanded appreciation and knowledge of women's health issues means more than just understanding the issues that directly impact oral health. Ongoing research and emerging information investigating possible mechanisms of action and confirming links between oral health and a woman's overall well-being makes it imperative that dental professionals expand their knowledge of medicine. The information in this course has relevance and application to the daily practice of dentistry as conscientious healthcare professionals assume an expanded role in the total care of their patients.

Education Category: Women's Health - Maternal / Child
Release Date: 02/01/2014
Expiration Date: 01/31/2017


This course is designed for dentists, dental hygienists, and dental assistants.

Accreditations & Approvals

NetCE is designated as an Approved PACE Program Provider by the Academy of General Dentistry. The formal continuing education programs of this program provider are accepted by AGD for Fellowship, Mastership, and membership maintenance credit. Approval does not imply acceptance by a state or provincial board of dentistry or AGD endorsement. The current term of approval extends from 10/1/2015 to 9/30/2021. Provider ID 217994. NetCE is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to ADA CERP at www.ada.org/cerp. NetCE is a Registered Provider with the Dental Board of California. Provider Number RP3841. Completion of this course does not constitute authorization for the attendee to perform any services that he or she is not legally authorized to perform based on his or her license or permit type. NetCE is approved as a provider of continuing education by the Florida Board of Dentistry, Provider #50-2405. NetCE is accredited by the International Association for Continuing Education and Training (IACET). NetCE complies with the ANSI/IACET Standard, which is recognized internationally as a standard of excellence in instructional practices. As a result of this accreditation, NetCE is authorized to issue the IACET CEU.

Designations of Credit

NetCE designates this activity for 5 continuing education credits. AGD Subject Code 149. This course meets the Dental Board of California's requirements for 5 unit(s) of continuing education. Dental Board of California course #05-3841-16150. NetCE is authorized by IACET to offer 0.5 CEU(s) for this program.

Course Objective

The purpose of this course is to provide dental healthcare professionals with a comprehensive update on healthcare-related issues affecting women.

Learning Objectives

Upon completion of this course, you should be able to:

  1. Discuss the role that oral health plays in the overall health of women.
  2. Describe the oral health manifestations associated with puberty and menstruation.
  3. Discuss the changes in the oral cavity associated with oral contraceptives and pregnancy.
  4. Identify the various types of cancer that affect women and describe how cancer treatments relate to women's oral health.
  5. Describe the role of hormone replacement therapy for the treatment of perimenopausal and menopausal symptoms.
  6. Identify strategies for the treatment and prevention of osteoporosis.
  7. Identify dental issues relevant to cardiovascular disease.
  8. Compare and contrast symptomatology and treatment of sexually transmitted infections.
  9. Identify the signs of eating disorders that may be identified by dental health professionals.
  10. Discuss the role of the dental health professional in identifying signs and symptoms associated with domestic violence.


William E. Frey, DDS, MS, FICD, graduated from the University of California School of Dentistry, San Francisco, California, in 1966. In 1975, he completed residency training in Periodontics and received a Master\'s degree from George Washington University. He has been a member of the American Dental Association for over thirty-five years, and is a member of the American Academy of Periodontology and a Fellow in the International College of Dentists (FICD).

Dr. Frey retired from the United States Army Dental Corps in 1989 after 22 years of service. Throughout the course of his professional career, he has continuously practiced dentistry, the first 7 years as a general dentist and the past more than 30 as a periodontist. His military experience included the command of a networked Dental Activity consisting of five dental clinics. In his last assignment, he was in charge of a 38-chair facility. Colonel Frey was selected by the Army to serve on two separate occasions as the Chair of the Periodontal Department in Army General Dentistry Residency Training Programs.

Dr. Frey currently maintains a practice limited to Periodontics in Jackson, California, and is the founder and president of Perio Plus, a practice management firm specializing in creating individually-designed hygiene and periodontal care programs for general dentists. He is also the creator of the Inspector Gum patient education series.

Gayle Roux, PhD, RN, CNS, FNP, received her BSN from University of Nebraska, and her MS and PhD in Nursing from Texas Women's University. She has been employed in various aspects of women's care including childbearing, family planning, and women's health. Currently, she practices as a family nurse practitioner and is faculty at Texas Woman's University. Dr. Roux's area of research is focused on inner strength in women living with chronic health conditions such as breast cancer. She lives in Dallas, Texas, and has two daughters. Dr. Roux enjoys cross-country skiing, traveling, and reading mystery stories.

Faculty Disclosure

Contributing faculty, William E. Frey, DDS, MS, FICD, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.

Contributing faculty, Gayle Roux, PhD, RN, CNS, FNP, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.

About the Sponsor

The purpose of NetCE is to provide challenging curricula to assist healthcare professionals to raise their levels of expertise while fulfilling their continuing education requirements, thereby improving the quality of healthcare.

Our contributing faculty members have taken care to ensure that the information and recommendations are accurate and compatible with the standards generally accepted at the time of publication. The publisher disclaims any liability, loss or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents. Participants are cautioned about the potential risk of using limited knowledge when integrating new techniques into practice.

Disclosure Statement

It is the policy of NetCE not to accept commercial support. Furthermore, commercial interests are prohibited from distributing or providing access to this activity to learners.

Table of Contents

Technical Requirements

Supported browsers for Windows include Microsoft Internet Explorer 9.0 and up, Mozilla Firefox 3.0 and up, Opera 9.0 and up, and Google Chrome. Supported browsers for Macintosh include Safari, Mozilla Firefox 3.0 and up, Opera 9.0 and up, and Google Chrome. Other operating systems and browsers that include complete implementations of ECMAScript edition 3 and CSS 2.0 may work, but are not supported.

#53381: Women's Health for Dental Professionals

  • Back to Course Home
  • Participation Instructions


In the last century, a virtual "knowledge explosion" has taken place with regard to women's health issues. In addition, there have been changes in the roles assumed by women in the home and in the workplace. Alterations and improvements in the pharmacologic and surgical treatment of many women's illnesses and health issues have also impacted outcomes and altered perspectives for long-term well-being and quality of life. For the dental healthcare professional, an expanded appreciation and knowledge of women's health issues means more than just understanding the issues that directly impact oral health. Ongoing research and emerging information investigating possible mechanisms of action and confirming links between oral health and a woman's overall well-being makes it imperative that dental professionals expand their knowledge of medicine. The information in this course has relevance and application to the daily practice of dentistry as conscientious healthcare professionals assume an expanded role in the total care of their patients.


Periodontal disease is one of the most common of human diseases. It is an infectious condition resulting in the destruction of the supporting apparatus of the teeth, the periodontal ligament, and alveolar bone. Its pathogenesis is inflammatory in nature, initiated by the accumulation of bacteria at or beneath the gingival margin in dental plaques and biofilms. There are an estimated 700 or more bacterial species in residence in the oral cavity. Their accumulation in various combinations and relative proportions create diverse and complex microbiologic communities that persist in great numbers in close proximity to the adjacent soft tissues of the sulcular wall [1,2].

The inflammatory response produced by these masses of micro-organisms results in an increase in epithelial turnover and a thinning and ulceration of the epithelial lining. The systemic circulation is thereby made accessible to a vast array and quantity of bacterial products, such as lipopolysaccharides (LPS), hydrolytic enzymes, and peptidoglycan fragments. The host response also produces cytokines and biologic mediators, such as interleukins and prostaglandins, in substantial amounts that also have ready access to the systemic circulation [3,4]. It is reasonable to speculate then that the presence of large numbers of bacteria, their products, and the products of the host response, all with ready access to the systemic circulation, may have an influence on overall health.


In the recent past when healthcare professionals thought about "women's health," their attention focused primarily on the patient's reproductive health. Times have changed. Women are assuming control over the elements and occurrences that may potentially impact their health and wish to make informed choices relative to every aspect of their health care. The definition of women's health has become not merely the absence of illness or disability, but has expanded to a broader, more comprehensive approach, encompassing physical, emotional, spiritual, and social dimensions of total well-being. Women appreciate healthcare professionals who listen and understand the full dimension of their concerns.

Although there are more women than men in the United States, women have long been underrepresented in medical research. To respond to this crucial need, the National Institutes of Health (NIH) in 1990 established the Office of Research on Women's Health (ORWH), which developed a research agenda to correct the gaps of knowledge in women's health. As a result, a record number of studies have been conducted, and more are underway, into areas such as heart disease, female cancers, gynecologic health, and osteoporosis, thus improving both the body of knowledge and therapeutic strategies for gender specific disorders. The ORWH has specified research priorities for the 21st century that include research on: the health of girls and women across the life span; sex and gender factors; biomedical, behavioral, and psychosocial factors; socioeconomic and geographic factors; women with disabilities; and the advancement of women in biomedical research careers [5].

Oral health is an important part of an individual's general health and well-being. This was a critical conclusion reached in the Surgeon General's report on oral health in America, which was first published in 2000 [6]. There are a number of oral-health issues unique to women, many of which are directly related to shifts in hormonal levels during puberty, menses, pregnancy, and menopause [7]. Oral bacteria may also have an influence on a number of systemic illnesses impacting women. There is emerging epidemiological and clinical evidence of an increased risk of mortality due to stroke and myocardial infarction and other causes in older patients with periodontal disease [8,9,10,11,12,13]. Researchers are continuing to expand and strengthen their understanding of the ways in which periodontitis and other oral-health conditions are associated with specific women's health concerns.

Many of the health problems that affect women today are amenable to community and public health approaches. Dentists, dental hygienists, and dental assistants are in a position to make a difference. Equipped with the information in this course, professionals whose main concern is oral health will expand their knowledge of women's healthcare issues and, with this knowledge, enhance their appreciation and understanding of the challenges women face. They should then be better equipped to identify and counsel their female patients on a number of health-related issues and to assist them in obtaining access and care for all of their health concerns.


The onset of menstruation, or menarche, is the most discernible female benchmark of puberty. Menarche now begins at an earlier age in Western nations, most likely because of improved nutrition and health care; higher relative weight is strongly correlated with the likelihood of having reached menarche at a younger age. Young women in the United States typically experience menarche at 12 or 13 years of age [14].

The members of the dental health team can provide factual information and clarify any myths or misconceptions about menstruation that their young female patients may have. There are also changes associated with menstruation that can have a direct bearing on oral health. When young women enter puberty, the changes in estrogen levels can be reflected by changes in the gingival tissues. The relative proportions of anaerobes in the subgingival plaque may change, coinciding with fluctuations in the normal hormonal cycle. Symptoms of gingivitis often follow a pattern that coincides with the menstrual cycle [15]. Nodular hyperplastic reactions that are histologically similar to inflammatory hyperplasia may take place. These areas frequently involve the interdental papillae and can be very red and exuberant in appearance. Patients with a familial history of juvenile periodontitis should be closely monitored for signs of periodontal disease, and appropriate therapy should be initiated at the earliest possible time. Referral for specialty evaluation is highly recommended [16].

Bleeding can become more extensive after oral surgery during the time of menses, and salivary glands may swell. A small rise in tooth mobility may also be detectable. Many women report that oral aphthous ulcers tend to appear during the luteal phase of their menstrual cycle [17]. These changes, however, are not universal and may vary in severity from one woman to another as levels of estrogen and progesterone fluctuate during the normal cycle. Dentists, hygienists, and dental assistants should educate patients on the importance of good dental hygiene and effective plaque control that can minimize the increase in gingivitis during menses.

Dysmenorrhea, or painful menstruation, usually occurs at or one day prior to the onset of menstruation and decreases during the menstrual cycle. Primary dysmenorrhea is painful menstruation with no detectable organic disease. Prostaglandins, produced by the uterus in high concentrations during menses, are the primary cause of the cramping pain. These prostaglandins increase uterine contractility and decrease uterine arterial flow, causing ischemia. The chief complaints of women with dysmenorrhea include cramps, abdominal pain, headache, malaise, and fatigue, plus aching in the back and thighs and gastrointestinal symptoms. Drug therapy includes prostaglandin inhibitors such as ibuprofen (e.g., Advil, Motrin), naproxen (e.g., Anaprox, Naprosyn, Aleve), and oral contraceptives [18]. Nonpharmacologic treatments include moderate exercise, rest, applications of moderate heat to the abdomen, balanced nutrition, and biofeedback.

Secondary dysmenorrhea is associated with pelvic pathology. Conditions that most frequently contribute to secondary dysmenorrhea include endometriosis, pelvic inflammatory disease (PID), uterine prolapse, or the presence of an intrauterine device (IUD). Because primary and secondary dysmenorrhea may coexist, an accurate differential diagnosis is important [18].

Premenstrual syndrome (PMS) is a cluster of symptoms that occurs two to three days before the onset of menstruation and then disappears during the first few days of the menstrual period. While the symptoms can vary greatly among women, they follow a consistent pattern of timing and symptomatology in each individual. Clinicians recommend that women keep a log for three months, which allows their individual patterns of PMS to be identified with greater accuracy, and thus appropriate therapeutic regimens can be recommended. Nonpharmacologic treatments include decreasing sodium and sugar intake, restricting caffeine, and performing regular exercise. Supplemental vitamin therapy, including B-complex vitamins, and especially B6, is effective for some individuals. Other pharmacological treatments include prostaglandin inhibitors and diuretics [19]. Sleep and rest are important as well.



Vaginitis is caused by a wide variety of organisms. These organisms can produce symptoms such as burning, itching, and vaginal discharge. Asymptomatic colonization may occur as well. Trends suggest that the incidence of yeast infections in particular is increasing, in part because of the widespread use of antimicrobial therapy. The organism most often responsible for vulvovaginal candidiasis is the fungus Candida albicans. Other species (e.g., C. glabrata and C. tropicalis) may also cause vulvovaginal candidiasis and are more resistant to treatment [20]. Vulvovaginal candidiasis is also commonly called moniliasis or referred to as a yeast infection [21,22,23,24].

A growing number of healthy, asymptomatic women now harbor C. albicans. A change in the vaginal environment and pH may cause the candida organisms to grow, resulting in the symptoms of vaginitis. The risk of yeast infections increases when women take an antibiotic for an infection in another part of the body that inadvertently impacts the balance of the normal flora of the vagina. Because these bacteria, by their presence, limit growth of Candida, their elimination may result in proliferation and the clinical signs and symptoms of a yeast infection [20,21,22,23,25].

This issue is particularly relevant for dentists if they routinely prescribe broad-spectrum antibiotics. As a result of research and education efforts, most dentists, as well as many of their patients, are aware of the risk of the development of a yeast infection when using broad-spectrum antimicrobial agents. Subsequently, these drugs are being prescribed less often than in the past. It is important to note that some women are more prone to develop yeast infections than other women and may do so even when antibiotics are not taken.


Over-the-counter antifungal medications (e.g., clotrimazole, miconazole nitrate) are available. These medications are convenient and economical for women who are well informed on the etiology and symptoms of fungal infections. If the vulva is also infected, a cream is available for topical application in addition to the intravaginal insertions. Yeast infections may be treated for 3 to 7 days with these agents. An infection that does not respond to topical treatment might respond to prescription medications, such as fluconazole, which is a 150-mg pill given in a one-time dose. Candidiasis itself does not pose a serious health risk; however, any infection that does not respond to treatment should be taken seriously [21,23]


Endometriosis is a condition in which cells from the uterine lining are found in other locations within the pelvic cavity. In women with endometriosis, endometrial cells have traveled through the fallopian tubes and implanted on other structures, such as the bladder, rectum, ovaries, and the outside surfaces of the uterus, vulva, and vagina. The exact incidence of endometriosis is unknown, but as many as 33% of women seen for pelvic pain, infertility, or pelvic mass are ultimately diagnosed with endometriosis [26]. The symptoms are caused by changes in the endometrial patches with the hormonal cycle. These patches thicken and bleed just like normally functioning endometrial tissues. The symptoms increase in severity over the years as the patches grow. Women with endometriosis often complain of pain, pelvic heaviness, hypermenorrhea, and pain radiating to the thighs. Scar tissue, infertility, and distortion or blockage of the affected structures may result.

The diagnosis of endometriosis is confirmed by laparoscopic identification of the patches. Treatment options vary, depending on the severity of the condition and the woman's childbearing choices. Because endometriosis may cause infertility, treatment should not be greatly delayed when childbearing is desired. Oral contraceptives are often helpful, as is treatment with danazol. Mild endometriosis is treated by surgically removing the endometrial patches. Women with severe endometriosis who do not wish to have children may consider hysterectomy [27].


Oral contraceptives (OC) are most commonly combinations of a progestational compound, such as norgestimate, and an estrogenic compound, such as ethinyl estradiol. In a general sense, their action mimics pregnancy, but they differ both in composition and action from the hormones that occur naturally. The apparent mode of action is by suppression of gonadotropins through the pituitary-hypothalamic axis, inhibiting ovulation. This hormonal suppression also alters the endometrium, lowering the likelihood of implantation, and affects the consistency of the cervical mucus, preventing sperm from entering the uterus [15,28].

There is an increased risk of several potentially serious conditions for patients taking OC. These include thromboembolism, myocardial infarction, stroke, hepatic neoplasm, and gallbladder disease. The risk, however, is very small in healthy woman without other underlying risk factors, such as hypertension, hyperlipidemias, obesity, and diabetes. Smoking is a substantial risk factor in the incidence of myocardial infarction for patients 35 years of age and older who take OC [29,30,31].

Gingival inflammation is a common side effect among women taking birth control pills, apparently due to changes in the microcirculation. There is also an alteration in the relative proportions in the established bacterial flora associated with the intake of these hormones. Prevotella species may overgrow disproportionately through a favorable increase in its nutritional supply, as female sex hormones may stereochemically resemble and substitute for the naphthoquinones needed by Prevotella[15,32,33]. Reports have also shown shifts in the makeup of saliva in women taking OC and other sex hormones. Salivary flow may change as well, with alteration in the rate of parotid and submandibular salivary secretions. There are also conflicting reports of chronic dry mouth in some women [34,35].

Published studies have indicated a greater incidence of postoperative localized osteitis in women taking OC after they have had their mandibular third molars removed. This may be related to the effect that birth control pills have on blood clotting. In one study, 40% of patients experiencing postoperative complications after third molar removal were users of oral contraceptives [32]. It was speculated that the increase of fibrinolytic activity associated with the use of OC accounted for the high incidence of postoperative complications. Such an increase was speculated to be associated with lysis of the formed clot and subsequent "dry socket" formation. As a result, some researchers have suggested that the risk of developing postextraction osteitis may be reduced by performing extractions on days 23 to 28 of the pill cycle, which are nonestrogenic days [32,36,37,38]. A study evaluating the impact of OC on women's periodontal health found that women who used OC had higher gingival-index scores and clinical attachment loss than nonusers [39].

Birth control pills, once absorbed in the stomach, are conjugated in the liver and enter the intestine in a conjugated, inactive form. The resident gut micro-organisms serve to restore the drug to its active form. It has been postulated that the effect of poorly absorbed, broad-spectrum antibiotics might significantly reduce the gut flora, thereby hindering this "reactivation" and resulting in the ineffectiveness of the drug and perhaps an unplanned pregnancy. The antibiotic effect is controversial. However, for as long as the manufacturer's precautions listed for an antibiotic include its possible effect on OC, it is prudent for all clinicians choosing to prescribe one of these antibiotics to advise their patients of the possible effect. Patients should be counseled to use an alternative form of birth control while taking the antibiotic [40,41].


A number of changes in the oral cavity have been associated with pregnancy, including caries, perimylolysis, tooth mobility, xerostomia, pregnancy granuloma, and ptyalism/sialorrhea [17]. Perhaps most commonly, the hormonal changes that occur during pregnancy have been linked with gingivitis. Shifts in hormone levels may cause changes in the established microbiota, with overgrowth of certain bacteria species, increases in the ratio of bacterial anaerobes to aerobes, and changes in the proportions of P. intermedia, Bacteroides melaninogenicus, and Porphyromonas gingivalis[17,42,43]. Pre-existing subclinical gingivitis may become exacerbated during pregnancy so that clinical signs become apparent, including swelling, redness, bleeding, and tenderness [44]. These signs may begin to be noticeable in the second trimester and peak around the eighth month. Anterior teeth may be more apparently involved than the posterior. Mouth breathing is a potential exacerbating factor. A woman who has poor oral hygiene runs the risk of even greater gingival problems, although gingivitis can develop in women with no changes in their plaque-management behavior. Postpartum studies have shown that after delivery, the mother's level of gingivitis decreases as the constituency of the microbiota changes back to approximate its prepregnancy status. With the inflammation comes an increase in tooth mobility. Xerostomia is also reported in a high percentage of patients.

In a study published in 2010, researchers evaluated the way in which changing hormone levels influenced the gingival tissues in 48 pregnant and 28 nonpregnant women. In analyses of the subjects clinically and microbiologically, the researchers found that the proportions of the subgingival pathogens did not differ during pregnancy but did differ significantly after delivery. Patients who were P. gingivalis-positive presented with increased gingival inflammation that was not related to plaque [43]. Receptors for female sex hormones are located on human gingiva. The presence of progesterone, for example, may lead to greater gingival exudate. The inflammatory response also appears to be triggered as levels of estrogen and progesterone rise [42,45,46,47].

In addition to generalized gingival changes, a solitary, tumor-like growth, frequently referred to as a "pregnancy tumor" or "pregnancy granuloma," may appear. This lesion is often found associated with anterior interdental areas and has a histologic appearance similar to a pyogenic granuloma. Often, the lesion will regress after delivery, so decisions about surgical removal are best delayed until some time postpartum. Also, removal of the lesion during pregnancy may result in a recurrence [17].

Women in their childbearing years should be informed of the increased likelihood of developing gingivitis and other conditions that may accompany pregnancy. Advice on how they might reduce their risk should be given, including increasing the frequency of their visits with their dental hygienist and optimizing the effectiveness of their plaque control.

Some women may experience gestational diabetes. When, through their clinical findings and the reaction to treatment procedures, clinicians suspect that a patient may have diabetes, an expanded heath history should be obtained, with inquiries regarding relatives who may have the disease or whether the patient has experienced diabetes during past pregnancies. Diabetics have a compromised ability to deal with infections, including periodontal disease. Research has also suggested that periodontal disease may influence the course of diabetes and affect glycemic control [48,49,50]. Results of a 2-year study demonstrated that patients with severe periodontitis at the baseline examination had a sixfold increased risk of poor glycemic control (glycated hemoglobin greater than 9%) at follow-up. An intervention study conducted in 1992 evaluated the effects of scaling and root planing and systemic doxycycline given over a two-week period on glycemic control [48]. The results suggested that there were potential systemic benefits of this approach in treating diabetic patients. Patients with better-controlled diabetes appear to derive the most benefit [51].


While infant mortality rates have declined, low birth weight in preterm infants remains a significant cause of infant morbidity and mortality. In spite of increased efforts to diminish these outcomes through preventive interventions during prenatal care that addresses traditional risk factors, these efforts appear to have only a minimal impact on the number of preterm low birth weight (PLBW) infants, with some research indicating weight increases of less than 1% [52]. Researchers are thereby investigating other, previously unrecognized risk factors that may contribute to the continuing prevalence of PLBW infants.

A number of studies have indicated that women with periodontal disease have an increased risk of preterm births [17,53,54]. A PLBW baby is defined as one born before the 37th week of gestation, weighing less than five pounds, six ounces. In a study of 124 pregnant or postpartum mothers at the University of North Carolina School of Dentistry, those who delivered preterm newborns were more likely to have significantly worse periodontal disease than a comparable group of women who delivered normal birth weight infants. The researchers concluded that periodontal disease is a statistically significant risk factor for preterm low birth weight, with an adjusted odds ratio of 7.9 [53].

Another study of 870 women with pregnancy-associated gingivitis conducted by the Department of Conservative Dentistry in Santiago, Chile, found that periodontal treatment significantly reduced the incidence of preterm labor and/or low birth weight infants [55]. In light of this and similar studies, the American Academy of Periodontology has recommended that periodontal evaluations be a part of prenatal care [56].

Although ongoing studies are exploring the way in which oral infections may trigger preterm births, several pieces of the puzzle have been postulated as to how the disease may affect delivery timing. For example, other types of maternal infections, including genitourinary infections, have been linked to premature labor, and certain bacteria similar to organisms associated with periodontal disease have been detected in the genital tracts of women at a higher risk for preterm birth. Within the oral cavity, periodontal plaque triggers an inflammatory process that leads to increases in levels of a number of substances, including prostaglandin E2 (PGE2) and tumor necrosis factor-alpha (TNF-a) molecules. The elevated presence of PGE2 can yield a molecule whose configuration is quite similar to oxytocin, which can induce labor. Thus, the presence of chemicals such as PGE2 may trigger preterm delivery [15,57]. A 2008 study found that maternal periodontal disease is associated with systemic inflammation and elevated serum C-reactive protein (CRP) levels, a marker of inflammatory processes, and other studies have shown that a very high CRP level early in pregnancy is a risk factor for preterm delivery [165,166].

The relationship between infection, especially genitourinary infections, and adverse pregnancy outcomes has been well documented in both animal and human studies. University of North Carolina researchers found that gingival crevicular fluid levels of PGE2 are significantly elevated in mothers of preterm low birth weight infants, compared with mothers of normal birth weight controls. Specifically, four micro-organisms associated with progressing periodontitis (i.e., Bacteroides forsythus, P. gingivalis, Actinobacillus actinomycetemcomitans, and Treponema denticola) were found in greater amounts in the mothers of preterm low birth weight infants, compared to controls [58]. In a separate study at Columbia University School of Dental and Oral Surgery, mothers of low birth weight infants had significantly increased levels of B. forsythus and Campylobacter rectus, as well as consistently higher levels of other species [59].

A number of other factors are known to contribute to the incidence of preterm infants, which now account for about 11.5% of all live births. It has also been reported that preterm births account for 35% of all U.S. healthcare spending for infants and 10% of spending for children as a whole [60]. Widely acknowledged risk factors include a poor diet, maternal age younger than 20 years or older than 35 years, multifetal pregnancies, various maternal health problems (e.g., high blood pressure, diabetes), and maternal intake of alcohol, nicotine, or drugs. The conclusions of a study conducted by the University of Alabama at Birmingham School of Dentistry led researchers to report that "poor periodontal health of the mother is a potential independent risk factor" for low birth weight infants [61]. This finding has also been reported by other researchers [62,63].

Treatment of periodontal disease in pregnant women, and in all women of childbearing age, could have a positive effect upon the incidence of preterm births, although evidence of this benefit is still scarce. Intervention studies have begun at several universities that should shed greater light on the interrelationship and how it may be favorably influenced [52]. The Columbia University researchers cited above found that 19.9% of women who did not receive periodontal intervention gave birth to PLBW infants, compared to 13.5% of women who did receive the therapy [59].


No woman is immune from contracting cancer. In the United States, women have a one in three lifetime risk of developing cancer [64]. Although some types of cancer (e.g., lung cancer, colorectal cancer) strike both sexes in large numbers, others affect women exclusively (or, in the case of breast cancer, almost exclusively).


Although the exact cause of cervical cancer is unknown, cervical cell changes may be the result of an "insult" from viruses and multiple sexual partners. Women with cervical cancer often report a history of cervical infections. The infections most frequently linked to cervical carcinoma are caused by herpes simplex virus type 2 (HSV-2); human papillomavirus (HPV) types 16, 18, 45, and 58; human immunodeficiency syndrome (HIV); and perhaps cytomegalovirus. However, HPV infection is almost always the cause of cervical cancer. These viruses alter the DNA in the nuclei of immature cervical cells [65,66,67].

The Papanicolaou (Pap) test, or smear, safely and inexpensively detects cervical cancer at an early stage. Dr. George Papanicolaou, a Greek physician, developed the Pap test in the 1940s, and it became a regular component of gynecologic examinations during the 1950s. Since then, the incidence of invasive cervical cancer and the death rate from cervical cancer have declined, but the number of women with cervical intraepithelial neoplasia (CIN) has increased at alarming rates [68]. As part of general health education, dental health professionals can help ensure that women understand the importance of Pap smears.

Recommendations regarding how frequently average-risk women should have Pap tests have changed significantly as of 2012. National health organizations, such as the National Cancer Institute (NCI) and the American Medical Association (AMA), have adopted consensus recommendations. Other organizations, such as the American Cancer Society (ACS), the American College of Obstetricians and Gynecologists (ACOG), and the U.S. Preventive Services Task Force (USPSTF), have developed updated guidelines for cervical cancer screening. Guidelines from the ACS, the ACOG, and the USPSTF are similar and are summarized below [68,69,70]:

  • Pap tests (cytology) should initiate at 21 years of age, regardless of positive history of sexual activity or other risk factors.

  • Cytology (conventional or liquid-based) should be performed every 3 years in women 21 to 65 years of age.

  • HPV screening is not recommended in women younger than 30 years of age.

  • At or after 30 years of age, HPV co-test screening (cytology plus HPV testing) may be performed every 5 years in women who wish to extend their screening interval; however, HPV testing alone is not recommended.

  • Screening is not recommended in women older than 65 years of age who have an adequate screening history.

  • Women who have had a total hysterectomy (with removal of the cervix) should discontinue screening. Women who have had a hysterectomy without removal of the cervix should continue to follow the screening guidelines.

  • Although most cases of cervical cancer are caused by HPV, women who have been vaccinated against HPV should continue to follow these guidelines because it is uncertain whether vaccination reduces the need for screening.

In 2006, the U.S. Food and Drug Administration (FDA) approved a quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine, Gardasil, to prevent vulvar and vaginal precancerous lesions and cervical cancer caused by these strains of HPV. The vaccine is approved for administration in girls and women 9 to 26 years of age [71,72]. This vaccine was the first of its kind to be made available. In 2009, a second HPV vaccine, Cervarix, was approved by the FDA for use in girls and women 10 to 25 years of age [167]. Cervarix protects against HPV strains 16 and 18 and contains a proprietary immune response boosting adjuvant that results in significantly higher serum neutralizing antibody titers compared to Gardasil [168]. In 2014, a 9-valent HPV recombinant vaccine (Gardasil 9) that adds protection to HPV types 31, 33, 45, 52, and 58 in addition to those types covered by the original Gardasil [183]. With this increased coverage, the 9-valent vaccine has the potential to prevent up to 90% of cervical, vulvar, vaginal, and anal cancers. Gardasil 9 is approved for girls and women 9 to 26 years of age and boys 9 to 15 years of age [183]. Several other HPV vaccines are in development or clinical trials.

There is hope that HPV vaccination will have a significant positive impact on public health. As discussed, it is uncertain whether vaccination reduces the need for cervical cancer screening, and because neither vaccine provides protection against all HPV strains, both vaccine manufacturers and the Centers for Disease Control and Prevention (CDC) recommend continuation of routine cervical cancer screening [69,169].

It is critical to emphasize to the professional and the public that healthcare appointments are needed for women to be assessed for sexual questions, risk factors, presence of sexually transmitted infections, contraceptive needs, blood pressure, weight control, clinical breast exam, and any other issues of concern.


The most common type of gynecologic cancer is cancer of the uterus, and approximately 50,000 women will be diagnosed with uterine cancer each year [74]. The three layers that comprise the uterus are the inner layer or lining, which is called the endometrium, the middle muscular layer, which is called the myometrium, and the layer of tissue that coats the outside of the uterus, which is known as the serosa. Most uterine cancers begin in the endometrium. Endometrial cancer occurs most often (75% of cases) in women older than 55 years of age [74].

Endometrial cancer is familial, and research is underway to identify genetic markers. Research has indicated that a relationship of mismatch repair (MMR) gene mutations to endometrial cancer may be present [75]. MMR genetic abnormalities are also considered causal in hereditary nonpolyposis colorectal cancer (HNPCC), which may be a risk factor for endometrial cancer. More research is necessary to fully understand the genetics involved in the development of HNPCC-associated uterine cancers.

Risk factors for endometrial cancer include advancing age, hormone imbalance, estrogen therapy, use of birth control pills, breast or ovarian cancer, early menarche (before age 12), infertility or no pregnancies, obesity, high-fat diet, diabetes, Lynch syndrome, and family history [65]. The only sign of endometrial cancer, especially in postmenopausal women, is abnormal vaginal bleeding. Women should be instructed to seek treatment when any vaginal bleeding occurs. A pelvic examination with an endometrial biopsy should be performed. If the result of the biopsy is positive, a total abdominal hysterectomy and bilateral salpingo-oophorectomy are performed. Other treatments, depending on the stage of the cancer, include radiation and chemotherapy. These tumors tend to be well differentiated and localized. If the tumors are detected and treated early, women with endometrial cancer have a high survival rate [74,76].


Ovarian cancer is the deadliest of all female reproductive system cancers because it is difficult to detect and diagnose at an early stage [77]. Frequently, by the time it is diagnosed, the cancer has already spread throughout the pelvis. Screening for early ovarian cancer remains a scientific challenge, and new methods are being researched.

Ovarian cancer occurs most frequently between 40 and 70 years of age. The exact cause is unknown; however, evidence suggests a link to endocrine function. Factors preventing ovarian cancer include those that decrease the number of times a woman ovulates. Thus, protection is provided in women who conceive before 25 years of age, experience early menopause, and/or use oral contraceptives for years. Ovarian cancer is familial; if a woman's mother or sister had ovarian cancer, the woman herself is as much as 50% more likely to develop it. Environmental risk factors include talc and asbestos exposure, as well as a high-fat diet. The alarming factor with ovarian cancer is its elusive lack of symptoms. The most common sign is an enlargement of the abdomen [77]. Women may complain of an inability to fasten their pants and skirts. Other symptoms may include vague abdominal fullness or discomfort, pelvic pain, and ascites. Treatment options include surgery, radiation, and chemotherapy. Paclitaxel (Taxol), a newer anticancer medication, has successfully treated progressive ovarian cancer; it is produced from the bark of the yew tree and is very expensive.


Breast cancer is the most common cancer in women, but it is also one of the most treatable if detected early. The risk to American women of developing breast cancer in their lifetime is reported as one in eight [78]. Nodal involvement remains the best prognostic indicator for long-term survival. The ACS has reported the five-year survival rate as 100% for Stage 0 or I, 93% for Stage II, and 72% for Stage III [79]. These survival rates underscore the importance of rigorous, consistent screening for all women.

The most widely accepted risk factors for breast cancer are age, gender, and personal and family history of breast cancer. The identification of genes associated with familial breast cancer has been a remarkable step forward in identifying risk factors for prevention. However, BRCA1 and BRCA2, the breast cancer genes, only account for 5% to 10% of the breast cancer cases in the United States [79].


The following breast cancer screening information is based on guidelines from the ACS and the NCI [81,82,83].

Breast Awareness

Women should be aware of changes in their own breast tissue, including lumps or swelling, skin irritation or dimpling, nipple pain or retraction (turning inward), redness or scaliness of the nipple or breast skin, or a discharge other than breast milk [82]. Although breast self-examination (BSE) has been recommended in the past, the NCI states that the harms of BSE may outweigh the benefits [81]. According to the NCI, BSE does not reduce mortality and leads to a greater number of biopsies and diagnosis of benign lesions.

The ACS and the ACOG recommend that women older than 20 years of age become familiar with the feel and appearance of their healthy breasts in order to recognize any significant changes [82,170]. The best time to examine the breasts is a few days after the menstrual period ends, when the breasts are least affected by hormonal changes, swelling, and fibrocystic changes. The examination is also most comfortable after the menstrual period because the breasts are less tender. In women who are menopausal, or who do not have regular periods, the BSE should be done on the same day every month, such as the first day of the month.

Clinical Breast Exam

The clinical breast examination (CBE) as part of breast cancer detection is another questionable practice; this is partially due to the lack of efficacy data from randomized controlled trials [81]. At this time it is not known if CBE reduces a woman's risk of dying from breast cancer. Although the experienced professional may find an irregularity that the woman has missed, according to the NCI the potential harms may outweigh the benefits. CBE is associated with a false positive rate as high as 12%; additionally, cancerous lesions are not found in up to 43% of women using CBE alone [81]. CBE of longer duration is associated with better diagnostic accuracy.

The ACS recommends initiating CBE at 20 years of age as an opportunity to discuss breast awareness technique/limitations and early detection with mammography [79]. The ACOG recommends CBE every 1 to 3 years in women 20 to 39 years of age and every year in older women; however, this is a C-level recommendation (i.e., based on consensus and opinion rather than consistent scientific evidence) [170].


A mammogram is a special x-ray that compresses the breast tissue between two plates. It identifies suspicious or malignant tissue, measures the size, and locates any spread of cancer in the breast. Most breast lesions are present for several years before they can be palpated, and thus mammography can detect lumps and breast cancer much earlier than manual breast examination, at the earliest stage of development. When detected early, the survival rate for women with in situ breast cancer is 98.6% [84].

In general, while regular mammograms should be performed annually beginning at 40 years of age, risk factors and informed choices will determine the schedule for those younger than 50 years of age. The benefits of annual mammography are based on consistent evidence; there is a 15% to 20% relative reduction of mortality in women 40 to 79 years of age [81]. However, the harms associated with mammography are also based on solid evidence that cannot be ignored. These include overdiagnosis and the resulting treatment of insignificant cancers (up to 54%); false-positives with additional testing and anxiety; and false-negatives with a delay in treatment (between 6% and 46% of women with invasive cancer will have a false-negative result). Below are the general screening guidelines for the techniques discussed [82,83,170]:

Breast Self-Examination:
Women may choose to initiate at 20 years of age
Clinical Breast Examination:
Every 3 years for those 20 to 40 years of age
Yearly after 35 years of age, if at risk
Yearly after 40 years of age
Yearly for those 40 years of age and older
If at higher than average risk, discuss starting earlier

Treatment Choices

A diagnosis of breast cancer threatens a woman's life, but it also can alter her self-image and change her roles, support systems, and family relationships. The varied choices of breast cancer treatment contribute to the complexity and confusion that the diagnosis can bring to a woman and her family and friends.

Not long ago, a diagnosis of breast cancer was usually followed by a radical mastectomy. Although surgery remains a primary component of treatment, now more breast tissue may be conserved, and surgery is typically combined with adjuvant therapies (i.e., chemotherapy, hormone therapy, radiation therapy). If the woman has carcinoma in situ (i.e., noninvasive breast cancer), the surgical procedure might be the modified mastectomy or lumpectomy; these surgeries remove the breast tissue and axillary lymph nodes but leave the pectoralis muscle intact [86]. Women with small tumors (less than 4 cm) and in an early stage of cancer (Stage I or II) are often good candidates for lumpectomy. In these women, lumpectomy with radiation has demonstrated the same survival rate as other surgical techniques, while preserving breast tissue [87]. For many women, breast cancer is a hormonally influenced malignancy. Cancer cells are tested following surgical removal, and hormone therapy is used when the cancer is sensitive to estrogen (i.e., estrogen receptor positive).

Women with locally advanced breast cancer (stage III) generally require neoadjuvant chemotherapy and/or radiation prior to any surgery to promote tumor shrinkage and allow for a more manageable surgical procedure [171,172]. Many of the chemotherapeutic agents prescribed for women's cancers have a pronounced effect on the oral mucosa. Multiple, painful ulcerations may be present, which may present a substantial therapeutic challenge to treat and ameliorate. Weight loss often takes place at a time when the patient could use all of the nutritional support she can get. Clinicians have prescribed oral rinses of local anesthetic agents, to be used at meal times or in combination with antibiotics to decrease the incidence of secondary infection, and antihistamines to reduce the inflammatory component. Antimicrobial oral rinses containing chlorhexidine gluconate have also been prescribed. Clinicians have also employed agents that coat the surface of the mucosa and cover the ulcerations. Such agents have a transient effect at best. There is no good solution for this problem.


The simplest definition of menopause is the end of menstruation. Although menopause literally means cessation of menses, menopause is actually a process rather than a discrete, single occurrence. It is defined as a transition of biological and cultural events over a period of months to years. An average life expectancy of 78 years means that the "average" woman will live one-third of her life after her last menstrual period [88,89,90,91].

Perimenopause refers to the stages of regression of ovarian function, which can be as long as 7 to 10 years. It culminates in the last menstrual cycle and extends at least one year after menopause. Menstrual periods stop when the ovaries no longer produce female hormones. This deficiency may cause symptoms such as hot flashes, vaginal dryness, emotional changes, and weight gain. Some women, however, are asymptomatic [87,89,90].


In the menopausal and postmenopausal periods, many women experience symptoms in their oral cavity, including dryness of the mouth, pain, burning sensations of the tongue, and changes in taste sensations [17,88,92,94,95,96]. There may be alterations in the oral mucosa as well, including thinning of the epithelial lining. A condition called menopausal gingivostomatitis has been identified, in which the gingiva becomes dry, bleeds easily, and may experience changes in color (from pale to very red) [17,97].

Before menopause, periodontal disease is more common in men than women. But in the postmenopausal years, women surpass men in the incidence of periodontal disease, except women who are on hormone replacement therapy (HRT). When informed that patients have discontinued an HRT regimen, typically because of concerns over the safety of the therapy, dental health professionals should show increased vigilance in detecting and treating periodontal symptoms.


To ease the transition into perimenopause, women should consider the following strategies [85,93,98,99,100,101]:

  • Exercise. Perimenopausal women should perform a program of moderate-intensity aerobic, weight-bearing exercise for at least 150 minutes per week. It is recommended that workouts last at least 10 to 15 minutes per session (30 minutes 5 days per week is ideal), in order to maintain an elevated heart rate for a prolonged period of time. Alternately, 25 minutes of vigorous-intensity exercise 3 days each week (a total of 75 minutes per week), or a combination of both, is recommended. If women need to achieve a healthy weight, 1 hour of moderate-intensity aerobic physical activity per day is recommended. Moderate-to-vigorous-intensity muscle strengthening activity performed 2 or more days per week is recommended for additional health benefits. Exercise has been shown to reduce bone loss, prevent weight gain, and improve overall well-being.

  • Diet. The American Heart Association recommends eating a balanced diet that consists of 6 daily servings of grains (at least 50% whole grains); 4 servings per day of vegetables (variety of colors); 4 servings per day of fruits (variety of colors); 2 to 3 servings per day of low-fat dairy products; less than 6 oz. meats per day; 2 or 3 servings per day of fats or oils (unsaturated); 3 to 4 servings of nuts, seeds, or legumes per week; and 0 to 5 servings per week of sugar or sweets.

  • Health screenings. Perimenopausal women should be screened routinely for early detection of women's health problems, as discussed. Additionally, a lipid profile, colorectal cancer screening, and blood pressure checks should be performed at recommended intervals. Women should get a dental exam every 6 to 12 months.

  • Hormone replacement therapy (HRT). Although not without risk, HRT is an option for the treatment of both the physical and emotional effects of menopause. It is optimal to use HRT at the lowest dose and for less than 5 years.

Hormone Replacement Therapy

Treatment for perimenopausal/menopausal symptoms and for the prevention of long-term risk factors associated with postmenopausal women has generated clinical discussion and research studies on HRT. Although HRT may help some women, the availability of these medications does not imply that all women should take them. In fact, research has called into question the advisability of the long-term use of HRT, and many physicians are re-evaluating the criteria they use for determining candidates for this drug therapy [102].

HRT and Cardiovascular Disease

The incidence of cardiovascular disease in women rises markedly after menopause. Research has shown that both natural and surgically induced menopause are associated with changes in serum lipid profiles, a decline in high density lipoproteins (HDL), and an increase in low density lipoproteins (LDL) [103]. These cholesterol changes may increase the risk of developing postmenopausal heart disease.

For years, many women were placed on HRT based on research such as the Nurses' Health Study, which reported that postmenopausal estrogen users had a reduced risk of coronary artery disease and fatal strokes compared with women who had never used estrogen [104]. Other studies suggested that postmenopausal estrogen had an independent, protective effect against cardiovascular disease.

But in 2002, surprising results from a major clinical trial, the Women's Health Initiative (WHI), were published in the Journal of the American Medical Association. The study was designed to evaluate the health benefits and risks of the most commonly used estrogen-plus-progestin hormone preparation in more than 16,000 menopausal women. The trial was halted after a mean follow-up of 5.2 years because of the apparent increased risks of coronary heart disease, stroke, pulmonary emboli, and invasive breast cancer associated with HRT. The authors of the study reported that the rate of women experiencing coronary heart disease events rose 29% in women taking HRT, compared to placebo. Stroke rates were 41% higher in the HRT group, while the rate of venous thromboembolism was about double in the drug cohort [99,100,102]. A 2005 review of the data from ten clinical trials (two involving healthy women; eight involving women with heart disease) reported similar findings [105].

HRT and Osteoporosis

Osteoporosis is one of the most serious long-term concerns of perimenopausal and postmenopausal women, affecting approximately one in four women [98]. The loss of bone mass accelerates after menopause and causes bones to become brittle and at increased risk of fractures. Hip fractures among elderly women are not only costly and debilitating, but women often die from subsequent complications within a year. Studies have shown that long-term estrogen use protects women from postmenopausal bone loss and osteoporosis [90]. Estrogen therapy slows the demineralization process, but it cannot restore bone that has already been lost. In addition, once estrogen replacement stops, bone loss resumes. The WHI trial did show that women taking the estrogen-plus-progestin formulation experienced a one-third reduction in hip fractures and a 24% decline in total fractures [102].

HRT and Cancer

During the 1970s, unopposed estrogen therapy was routinely given to menopausal women with an intact uterus, which resulted in an increased risk of endometrial hyperplasia and cancer. Adding progesterone to estrogen, however, greatly decreased the risk of endometrial cancer. HRT advocates argued that the risks of endometrial cancer were low and rare compared with the reported cardiovascular and osteoporotic benefits. For years, the link between breast cancer and HRT remained controversial. Some studies suggested that lower doses of estrogen did not increase the risk of breast cancer while others suggested the opposite. Comparison of existing studies was difficult due to selection biases and other methodological differences.

But the WHI trial strongly fell on the side of increased breast cancer risks associated with HRT. The trial found that invasive breast cancer rates increased by 26% in women taking hormone therapy. At the same time, HRT users showed a 37% reduction in colorectal cancer rates [102,106].

HRT and Alzheimer's Disease

Observational studies have indicated that long-term estrogen deficiency seems to be related to a higher risk of developing Alzheimer's disease [107]. Among the 5 million people 65 years of age and older in the United States with Alzheimer's disease, 3.2 million are women and 1.8 million are men [181]. Women also suffer more severe cognitive impairment [108]. The finding that women with Alzheimer's disease have lower levels of estrogen than do those without Alzheimer's disease seems to indicate that there is a relationship that bears further investigation; however, HRT is not recommended for cognitive improvement or maintenance in women with Alzheimer's disease [109,110,111].

The Future of HRT

Previously, women taking HRT needed to follow a schedule of two tablets, which was both confusing and inconvenient. Regular menstrual-like flow occurred at the end of the 28-day cycle of medications. In 1995, combined estrogen/progesterone tablets became available in two different HRT regimens; a continuous therapy regimen and a cyclic regimen. This increased the convenience for women on hormone replacement therapy who have an intact uterus. However, in light of the findings of the WHI trial, many women have been or will be removed from HRT therapy, while others are taking it only for short-term management of symptoms [102]. The USPSTF recommends against the use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women and women who have had a hysterectomy [173]. As a result of research indicating the potential harms of HRT, many women are looking to nondrug approaches to manage their menopausal and postmenopausal symptoms, including dietary modification, exercise, and calcium supplementation for osteoporosis prevention.


Of all skeletal disorders, osteoporosis is the most common. It results from decreased density, or thinning, of the bone related to the aging process. Osteoporotic bone is more porous and is weaker than normal bone; thus, it fractures more easily. This condition is the leading cause of bone fractures in postmenopausal women and is associated with long-term disability, frailty, and enormous expense. Common sites for fractures are the spine, wrists, forearms, and hips. With the exception of arthritis, osteoporosis is the leading cause of musculoskeletal disturbances in the elderly [112].


Research seems to indicate that the loss of bone mass associated with osteoporosis may be associated with the incidence and severity of periodontitis. However, some of these clinical trials have evaluated small numbers of patients, and the control of potentially confounding factors has been inconsistent; the criteria used to define osteoporosis and to assess systemic bone density has also varied [113]. Nonetheless, a 2013 literature review found that 4 of 5 longitudinal studies, 20 of the 25 cross-sectional studies, and all 3 of the case-control studies reviewed showed an association between osteoporosis and periodontal disease [174].

Studies also support a relationship between osteoporosis and clinical attachment loss. While conclusions of the existing trials conflict with one another at times, the general consensus seems to be that an association may exist [113]. In a 1996 study of 42 postmenopausal women, 22 of whom had low spinal bone mineral density (BMD), low BMD showed a significant relationship to the presence of periodontitis and the loss of clinical attachment level [115]. Another study found that individuals with osteoporosis had a greater likelihood of tooth loss than nonosteoporotic individuals [116]. Women who had experienced osteoporotic fractures also seemed to have an increased risk of loss of periodontal attachment [117].

In one case-control study, 12 women reporting a history of osteoporotic fractures were compared with 14 normal controls. The subjects were evaluated for gingival bleeding, plaque, and loss of attachment, and BMD was tested using dual-photon absorptiometry for the mandible and forearm. The osteoporotic subjects had significantly greater loss of periodontal attachment than the controls, and significantly less bone mineral content in the measured bones. There were no differences in gingival bleeding and plaque in the two cohorts [117,118].

The use of HRT appears to decrease the incidence of tooth loss in older women. In the Nurses' Health Study, which evaluated more than 42,000 postmenopausal women prospectively, the risk of tooth loss was lower in women taking HRT, after controlling for age and smoking [114]. A study of women in a California retirement community found that after adjusting for age, the use of estrogen replacement significantly decreased tooth loss and rates of edentia by 36%; the proportion of women with edentia declined with lengthier use of HRT [119].

Bisphosphonate drugs, such as alendronate, may retard the progression of alveolar bone loss associated with periodontitis. In one double-blind, placebo-controlled clinical study, alendronate lowered the risk of progressive loss of alveolar bone loss; during the 9-month trial, the relative risk of the loss of bone height and density was reduced to 0.45 in the alendronate group [120]. Two other studies support the assertion that bisphosphonates may be useful for periodontal treatment; however, existing information on this potential is limited [121,122,123]. However, bisphosphonate drugs are known to cause bisphosphonate-related osteonecrosis of the jaw (BRONJ) in some patients, particularly those who underwent IV bisphosphonate therapy, who were taking bisphosphonates for extended periods of time, and/or who underwent dental procedures while taking bisphosphonate drugs [175,176].


Osteoporosis affects approximately 25 million of the estimated 40 to 50 million menopausal women in the United States, and is responsible for more than 1.5 million fractures each year [112]. Diagnosis of this disease in an aging population is challenging, even though impressive progress has been made. Bone densitometry is the procedure that measures bone mineral density. Dual-energy x-ray absorptiometry (DEXA or DXA) has become the routine method for bone density measurement. It is very precise and has the advantage over other, older diagnostic methods of a much shortened examination time (i.e., 2 minutes versus 20 to 40 minutes) [124]. DEXA is of particular advantage in measuring the lumbar spine and proximal femur areas and has become the gold standard for bone densitometry.

Various drug therapies exist for osteoporosis, and research findings suggest the possibility of newer treatments on the horizon. One of the most commonly prescribed drugs for women with osteoporosis is alendronate sodium, a bone resorption inhibitor. Alendronate has proven effectiveness in preserving bone tissue and decreasing bone loss. Calcitonin is a bone metabolism regulator that slows the rate of bone turnover and seems to increase normal bone formation. It is indicated for the treatment of osteoporosis in women: who have been postmenopausal for at least 5 years; who have low bone density; who refuse or cannot tolerate estrogens; or in women for whom estrogens are contraindicated. It has not been recommended as a first-line treatment [125]. Calcitonin decreases bone resorption by inhibiting the activity of osteoclasts. Increases in bone mass of 1.5% to 13% have been reported, with the best responses noted in individuals with the highest bone turnover [126,127].

In 2011, the FDA approved denosumab for treatment of osteoporosis in postmenopausal women who are at high risk of fracture [127,177,178]. Denosumab acts by binding to and inhibiting receptor activator of nuclear factor kappaB ligand (RANKL). RANKL controls the differentiation, proliferation, and survival of osteoclasts. Inhibition of RANKL provides a lengthened period of absorption and inhibition of bone resorption [127,179].


Because most postmenopausal women have some degree of osteoporosis, they should take steps to prevent further bone loss. The best preventive measures are early education to encourage positive lifestyle habits before the disorder develops (ideally, well before menopause). The following methods have been identified as being helpful to prevent bone loss [112,128,129]:

  • Consume up to 1500 mg a day of calcium.

  • Raise vitamin D intake to 400 to 800 IU daily.

  • Stop smoking.

  • Limit the intake of alcohol, coffee, and soft drinks.

  • Perform at least 1 to 3 hours of weight-bearing exercise per week.

Dairy products provide approximately 75% of the calcium in the average American's diet. However, the average daily calcium intake for women from dietary sources is only about half of the recommended amount. Women should be advised that it takes only three 10-ounce glasses of milk to supply 1,000 mg of calcium. Those who require more dietary calcium may choose to take supplements.


Coronary heart disease (CHD) is still generally thought of as a man's disease. Yet, according to the American Heart Association, of the 83.6 million Americans with one or more types of cardiovascular disease (CVD), more than half (42.9 million) are women. Women account for 51% of the deaths from CVD [130]. Heart disease is the leading killer of women.

Women tend to show signs of cardiovascular disease later in life than men. Between 20 and 59 years of age, men have a higher prevalence of CVD than women [130]. Although menopause decreases a woman's protection from heart disease, her biologic advantage persists until 65 to 70 years of age. Older women who have heart attacks, however, are twice as likely to die within a few weeks as men [76,131,132]. Dentists, dental hygienists, and dental assistants can play a key role in educating patients about heart disease in women, which is particularly important because of the research linking periodontal disease to cardiovascular disease.


CHD signs and symptoms differ significantly between men and women. Women tend to have angina pectoris as the first symptom of heart disease; men initially have a myocardial infarction. Women rarely experience myocardial infarction as the initial manifestation of heart disease [65,133]. Diagnosis of coronary disease in women is difficult. Women may have unspecified, misleading pain, which often results in a search for other causes. In the past, women have not been included in major cardiovascular research and treatment. This has greatly compromised the discovery of facts concerning the early identification and treatment of heart disease in women and is only now being rectified.


Women may have combinations of negative social, psychological, cultural, physical, and addictive behaviors that increase their CHD risk. The major modifiable risk factors are cigarette smoking, high blood cholesterol, high blood pressure, diabetes, physical inactivity, excessive alcohol consumption, stress, and excessive weight gain. Women who smoke and also have high blood pressure and high blood cholesterol levels are eight times more likely to develop heart disease than those who do not. Women who have diabetes are four to six times more likely to die from CHD than women without diabetes [65].

Dental health professionals should make sure patients understand that heart disease is not an inevitable consequence of aging; rather, it is a disease process that can be greatly influenced by lifestyle modification. Factors such as diet, exercise, not smoking, maintaining normal weight, monitoring blood pressure and cholesterol, and taking hormone replacement therapy (when appropriate) are all beneficial health behaviors.


There is some evidence linking poor dental health with heart disease, particularly in studies that have shown a link between periodontitis and CHD. For example, a study by Helsinki University Central Hospital evaluated 100 patients with acute myocardial infarctions and 102 controls, and graded their dental health. The researchers found that dental health was significantly worse in the patients who had experienced a heart attack, compared to the controls, even after adjusting for factors such as age, socioeconomic class, cholesterol (total, HDL) and triglyceride levels, C-peptide levels, diabetes mellitus, and smoking [134]. A separate study by the same researchers in Finland concluded that dental infections were associated with the pathogenesis of atherosclerosis, which is the only characteristic other than traditional coronary risk factors that showed an independent association [135]. Subsequent studies have confirmed the association between chronic oral infections and myocardial infarction [136,137,138].

The National Health and Nutrition Examination Study (NHANES I) evaluated more than 9,000 people for a median of 14 years and found that individuals with periodontitis had a 25% greater likelihood of developing CHD (an association found to be statistically significant). Poor dental hygiene characterized by extensive dental debris and calculus also increased the risk of CAD [139].

One hypothesis explaining the possible mechanism responsible for the link between CVD and periodontitis centers on bacterial products, such as lipopolysaccharides (LPS), that can enter the bloodstream and affect the cardiovascular system. Several studies have reported the presence of periodontal bacteria in cardiovascular specimens [140]. It has also been postulated that micro-organisms normally present in the oral cavity, including P. gingivalis and Streptococcus sanguis, enter the bloodstream through local action that induce bacteremias, grow within the vascular plaques, and have the potential to induce platelet aggregation [141]. A study of carotid atheromas using polymerase chain reaction found that 42% of atheromas contained at least one of the periodontal micro-organisms studied and 72% contained the bacterial DNA of one of these micro-organisms [142]. Although periodontal treatment as a means to prevent CVD is not recommended, the emergence of periodontal infection as a risk factor for CVD should lead dental and healthcare professionals to recognize that patients cannot be healthy without good oral health [143].


Environmental factors and lifestyle choices have an enormous influence on public health. This is particularly true for sexually transmitted infections (STIs). Although the organisms, modes of transmission, and complications resulting from STIs are well known, healthcare professionals have not been able to control these diseases, and their prevalence has increased over the last few decades.

Dental health professionals may encounter these infections in patients who have oral manifestations of STIs, which are most often contracted via oral-genital contact. For this reason, dentists and hygienists should be able to recognize unusual lesions, determine a diagnosis, and refer the patient to a physician for appropriate treatment. When discussing STIs with patients, the dental health professional should display a nonjudgmental attitude. Good communication is a hallmark of the relationship between the dental professional and the patient, and this is all the more true regarding communication about sexuality. Many patients may not understand that STIs can be transmitted through oral sex. In explaining how an STI may have been contracted, the dentist or hygienist who uses clinical terms might be regarded by the patient as too "medical," and the patient might not understand the terminology. The patient might also find the topic to be embarrassing. A soft voice and touch, eye contact, active listening techniques, and body posture can all assist in communicating a caring and nonjudgmental attitude.

There is considerable variation in the symptoms of and treatment options for STIs. The following information is a general guide to the major STIs found in the United States. More detailed information is available from the CDC and local public health agencies.


Gonorrhea, which is caused by the bacteria Neisseria gonorrhoeae, was once the most prevalent STI in the United States. Gonorrhea is one of the most common infectious diseases, with an estimated 820,000 persons in the United States acquiring the disease each year. After a decline in the incidence of the disease from 1975 to 1997, the national rate for gonorrhea has been steadily increasing. This STI is transmitted vaginally, orally, or anally by sexual activity or from the mother to newborn during delivery. The majority of women are asymptomatic early in the disease. When symptoms do occur, they may include burning on urination and increased vaginal discharge. In the oral cavity, the disease manifests as a stomatitis and may exhibit a clinical appearance similar to the oral lesions of erythema multiforme, erosive lichen planus, or herpetic stomatitis [144,145].

If the infection is in the oral cavity, diagnosis is made via bacteriologic evaluation of smears of the oral lesions. For infections in the genital area, gonorrhea is diagnosed in women with a culture of the cervical area. Both sexual partners should be tested and treated if either has a positive test for gonorrhea. Patients infected with gonorrhea are often co-infected with chlamydia and routinely treated with a regimen effective against both organisms.The recommended treatment of uncomplicated urogenital, anorectal, and pharyngeal N. gonorrhoeae infection in the United States is combination therapy with ceftriaxone 250 mg IM and either oral azithromycin 1 g as single dose or oral doxycycline 100 mg twice daily for 7 days [182]. Women should be informed of the need for retesting to verify eradication of the infection.


Syphilis is a bacterial STI caused by the spirochete Treponema pallidum. Like gonorrhea, syphilis is transmitted vaginally, orally, or anally through sexual activity, and via maternofetal transmission. In some cases, the disease has been acquired by dentists and hygienists providing dental treatment for a patient with syphilis during a contagious stage of the disease. Universal precautions apply, with the routine use of gloves, mask, and eye protection. Although syphilis is not as widespread as gonorrhea, its incidence is on the rise, which is especially ominous because of the harmful effects the untreated bacterium has on the heart, eyes, and central nervous system [145].

In the first stage of syphilis, a painless, ulcerlike lesion called a chancre appears at the site of the infection, which may include the oral cavity and lips, on average about three weeks after contact with the infectious agent. On the lips, the chancre is often crusted and brownish, while intraoral lesions tend to be covered by a grayish, white membrane [144]. The chancre disappears within a few weeks, but if the syphilis is untreated, the bacteria continue to proliferate within the body. The untreated syphilis may progress through secondary and tertiary stages. During the secondary stage, there can be multiple oral lesions manifesting as painless, grayish-white plaques, most often found on the gingival, tongue, or buccal mucosa. They may have an irregular shape and are extremely contagious. These secondary signs and symptoms will resolve, with or without treatment; however, without treatment, the infection will progress. The tertiary lesions may not develop for a number of years, most frequently affecting the cardiovascular and central nervous systems. In the mouth, tertiary lesions are far more commonly observed than the primary or secondary lesions and are most often manifested by an interstitial or atrophic glossitis. There is a reported predilection for this luetic glossitis to undergo transformation to carcinoma [144,145].

Diagnosis is established by blood tests, which determine the presence of antibodies in the blood. Treatment includes antibiotics such as penicillin, doxycycline, tetracycline, or erythromycin. The preferred treatment for patients not allergic to penicillin is a single dose of penicillin G [146]. The preparation, dosage, and length of treatment depend on the stage and clinical manifestations of the infection. Although syphilis can also be transmitted from an infected mother to her fetus (so-called congenital or prenatal syphilis), this form of the infection is very uncommon today due to routine blood tests conducted as part of prenatal care. In these cases, lesions may occur in any region of the oral cavity and tend to have a pink or red color [144].


Herpes can be manifested either as a genital or oral viral infection. When it begins in the genital area, the infecting agent has historically been identified as herpes simplex virus type 2 (HSV-2), but herpes simplex virus type 1 (HSV-1) now accounts for up to half of genital herpes infections [180]. Similar to other STIs, HSV may be transmitted vaginally, orally, or anally through sexual activity and to a newborn during delivery. Herpes is most contagious during active outbreaks of the disease when lesions are present, but cells may be shed at other times. Latex condoms used during genital or oral sex are effective barriers to HSV [145].

HSV-1 is often found in the oral cavity and presents with signs and symptoms similar to HSV-2. A herpetic infection can be designated as primary in individuals not previously exposed, who have not yet developed antibodies to the virus, or recurrent in patients with previous exposure who have antibodies present. The primary infection often presents as a generalized stomatitis. Individual and discreet lesions typically appear after a prodromal sensation reported by many patients six to eight days after infection. Papules appear and develop into blisters that may become extremely painful ulcers. Although the clinical manifestation may heal and disappear, the virus is still present in the patient, often at a location remote to where the lesions occur [145]. Recurring outbreaks may be related to stress, hormonal changes, trauma, exposure to ultraviolet sunlight, or fatigue.

Diagnosis of HSV-1 and HSV-2 is made by clinical inspection and culture of the sores. Herpes does not have a cure, but antiviral drugs such as acyclovir (Zovirax) and famciclovir (Famvir) can help relieve pain, speed healing, and possibly decrease the incidence of outbreaks [23,146].


An infection with Chlamydia trachomatis is the most common bacterial STI in the United States [65,69,146]. Although many infected women are asymptomatic, any one of the following symptoms may occur 1 to 3 weeks after contact: frequent, uncomfortable urination; dyspareunia; cervicitis with scant cervical discharge; lower abdominal pain; and/or pelvic inflammatory disease (PID) [146]. Antibiotic treatment includes drug protocols of azithromycin 1 g orally in one dose, or a course of doxycycline [127,146]. Pregnant women should be treated with azithromycin or amoxicillin, as the members of the tetracycline family (e.g., doxycycline hyclate) should be avoided during the time of fetal tooth development due to the well-known possibility of permanent staining of the teeth.


Human papillomavirus (HPV) causes condyloma (i.e., genital warts). It is the most common viral STI and is highly prevalent among young, sexually active individuals. HPV is transmitted by skin-to-skin contact rather than via the exchange of bodily fluids [147]. More than 100 types of HPV have been identified, and more than 40 can infect the male and female genital tract [145]. High-risk HPV identified in genital cancers include types 6, 18, 45, and 58 [66]. Women are more susceptible to HPV infection than men because cells in the cervix divide swiftly, facilitating the spread of the virus. Most HPV infection is not visible to the naked eye, but genital warts that appear as small bumps or groups of bumps in the genital area are the most common recognized visible manifestation [66]. Diagnosis is made by inspection, colposcopy, biopsy, or cytology. There is no treatment for the virus, but there are treatments for the diseases that HPV can cause. Patient-applied and provider-applied treatments are available. Factors affecting the choice of treatment include wart size, number, location, morphology, cost, and convenience. Imiquimod 5% cream is used in the treatment of external genital warts. Cryotherapy with liquid nitrogen may also be used in treatment [66,145]. HPV is preventable by adopting safer sexual practices; women should limit the number of partners and use latex condoms. In addition, it is recommended that all girls 11 to 26 years of age, who have not completed the vaccine series, receive the HPV vaccine [145].


HIV is the virus that causes acquired immunodeficiency syndrome (AIDS). Safer sexual practices to prevent HIV include limiting the number of partners, avoiding unprotected anal intercourse, and avoiding contact with the blood, semen, or vaginal secretions of others, including via the oral route. Women with HIV infection may experience remissions with medication regimens and improved supportive therapy that make it possible to regain high concentrations of T4/CD4 cells. However, some emerging HIV strains have proven to be resistant to current drug therapies [148].

Kaposi's sarcoma, a malignancy that may affect the skin or oral cavity, is a common complication of late-stage AIDS. Oral lesions associated with Kaposi's sarcoma most commonly appear on the palate, but may manifest anywhere in the mouth [24].


Eating disorders, such as anorexia nervosa and bulimia nervosa, can significantly impact oral health through a lack of proper nutrition and the effects of repetitive vomiting. They affect primarily young women and are a particular concern in women's oral health [149]. As many as 95% of bulimics and anorectics are female, mostly those in middle- to upper-class socioeconomic groups and with a typical onset from 17 to 21 years of age [150]. The results of a national screening initiative of U.S. high school students indicated that 25% of girls and 11% of boys reported disordered eating and weight control symptoms that were severe enough to warrant clinical evaluation [151].

The frequent, self-induced vomiting in conditions like bulimia, typically after periods of binge eating, can have a destructive effect on the teeth. The regurgitated gastric contents can cause decalcification, softening of the enamel, and loss of tooth structure. Most often, this erosion occurs on the maxillary anterior teeth—specifically, on their palatal surfaces. A loss of occlusal anatomy can be observed when the posterior teeth show evidence of damage [150,152]. Dental manifestations may not be immediately apparent, most often appearing after about two years of chronic vomiting.

The extent of erosion can vary from one patient to another and is often affected by the extent to which the low pH stomach contents are regurgitated. If these contents are regurgitated fully, the enamel erosion may be limited. Although treatment of the eating disorder is crucial, patients who continue to vomit can use interim measures to neutralize acids and thus reduce damage in the oral cavity [150]. One measure includes postvomiting rinsing with a preparation made with 1 quart of water combined with 1 teaspoon of baking soda. Fluoride rinses may also help to prevent the incidence of caries secondary to the erosion.

Dentists and other dental health professionals may notice other signs of eating disorders. For example, there may be trauma to the pharynx and the oral mucosa membranes related to the rapid intake of food and the abrupt, forceful vomiting that follows. The soft palate can also be affected when fingers or objects like pens are used to trigger vomiting. The parotid glands and, to a lesser degree, the sublinguals tend to swell in the presence of repeated binging and purging, seemingly related to numerous vomiting episodes. When salivary gland swelling does occur, it may be associated with cholinergic stimulation of the glands that occurs during regurgitation [149,153,154].

Dental care professionals often are the first to see the signs of eating disorders (e.g., dental erosion, traumatized oral mucosal membranes) that indicate appropriate referrals for medical or psychiatric care. Although the role of dental care professionals in this regard is well established, research has indicated that many lack knowledge about the oral and physical cues of anorexia and bulimia. A study of 576 dental care providers randomly selected from the American Dental Association and the American Dental Hygienists' Association indicated low scores concerning the providers' knowledge about the oral and physical cues of anorexia and bulimia [152].

Early identification of eating disorders is critical because they can cause significant complications (e.g., dehydration, abnormal heart function, GI complications) and are potentially fatal. Early identification, referral, and treatment of eating disorders may also help reduce the likelihood that the disorders will become fully developed [149,152,155].


Unfortunately, domestic violence, including emotional, psychological, and physical abuse, is common. Dental health professionals may be the first healthcare providers that a victim encounters. Therefore, they may play a critical role in identifying a battered woman. For this reason, they should be aware of the signs and symptoms associated with domestic violence.

The obvious signs are the physical ones, including the loss of or injury to teeth. Injuries may also range from bruises, cuts, black eyes, concussions, broken bones, and miscarriages, to permanent injuries, such as damage to joints, partial loss of hearing or vision, and scars from burns, bites, or knife wounds. Typical injury patterns include contusions or minor lacerations to the head, face, neck, breast, or abdomen. These are often distinguishable from accidental injuries, which are more likely to involve the periphery of the body. In one hospital-based study, domestic violence victims were thirteen times more likely to sustain injury to the breast, chest, or abdomen than accident victims. Abused women are also more likely to have multiple injuries than accident victims. When this pattern of injuries is seen in a woman, particularly in combination with evidence of an old injury, physical abuse should be suspected [156,157,158].

In addition to physical signs and symptoms, battered women also exhibit psychological clues that resemble an agitated depression. As a result of prolonged stress, these women often manifest various psychosomatic symptoms that generally lack an organic basis. For example, they may complain of backaches, headaches, and digestive problems. They often describe fatigue, restlessness, insomnia, or loss of appetite. Great amounts of anxiety, guilt, depression, or dysphoria are also typical [159,160,161,162].

As difficult as it may be to ask patients about domestic violence, as many as 30% of female trauma patients will report that they have been battered when asked directly about how an injury occurred [163]. Obviously, some women will not admit to a history of being battered. However, any trauma that seems incompatible with a history of the injury is suggestive of battering and indicative of the need for gentle questioning about how things are at home.

After identifying a victim, dentists and other healthcare professionals should immediately implement a plan of action that may include providing a referral to a local domestic violence shelter to assist the victim and the victim's family. The acute situation should be referred immediately to local law enforcement officials. Other resources in an acute situation include crisis hotlines and rape relief centers. After a victim is introduced into the system, counseling and follow-up are generally available with counselors who specialize in the care of battered women and their spouses and children. These counselors may include social workers, psychologists, psychiatrists, other mental health workers, and community mental health services. The goals are to make the resources accessible and safe and to enhance support for women who are unsure of their options [162,164].


Although dentists, dental hygienists, and dental assistants are concerned primarily about oral health, they can also play an important advisory role in the overall health of their female patients. The oral health of women (as well as men) cannot be separated from their total health, and by offering information, support, and community resources, the dental professional can and should be an integral part of the healthcare team.

This course has reviewed many of the key health concerns that female patients may be encountering. By taking a leadership role in promoting primary prevention, healthy lifestyles, and prompt and appropriate treatment, both in and out of the dentist's chair, your patients may lead longer, higher quality lives. You can make a difference in making progress toward improving women's health.


American Cancer Society
250 Williams Street, NW
Atlanta, GA 30303
(800) 227-2345
American Congress of Obstetricians and Gynecologists
P.O. Box 70620
Washington, DC 20024
(202) 638-5577
American Dental Assistants Association
35 East Wacker Drive, Suite 1730
Chicago, IL 60601
(312) 541-1550
American Dental Association
211 East Chicago Avenue
Chicago, IL 60611
(312) 440-2500
American Dental Hygienists' Association
444 North Michigan Avenue, Suite 3400
Chicago, IL 60611
(312) 440-8900
American Heart Association
7272 Greenville Avenue
Dallas, TX 75231
(800) 242-8721
Centers for Disease Control and Prevention
1600 Clifton Road
Atlanta, GA 30333
(800) 232-4636
National Cancer Institute
BG 9609 MSC 9760
9609 Medical Center Drive
Bethesda, MD 20892
(800) 422-6237
National Osteoporosis Foundation
1150 17th Street NW, Suite 850
Washington, DC 20036
(800) 231-4222
Office on Women's Health
200 Independence Avenue SW
Washington, DC 20201
(800) 994-9662
Women's Health Initiative
P.O. Box 30105
Bethesda, MD 30105
(301) 592-8573


Bone densitometry: Bone densitometry gives a quantitative measure of the bone mass by calculating a mean value with a standard deviation. This diagnostic test allows the clinicians to estimate the client's risk of fractures and determine whether treatment is needed to prevent further osteoporosis and risk of fractures.

Dietary calcium: Dairy products are the most common source of calcium in the American diet. Skim milk, 1 cup, has 302 mg of calcium; yogurt, low-fat, 8 ounces, has 415 mg of calcium; and cheddar cheese, 1½ ounces, has 306 mg of calcium.

Dysmenorrhea: Severe uterine pain usually occurring at or one day prior to the onset of menstruation and decreasing during the menstrual cycle.

Endometriosis: A condition in which endometrial cells implant on other parts of the body (e.g., bladder, rectum, ovaries, outside surface of the uterus), causing symptoms that include pain and pelvic heaviness.

Hormone replacement therapy (HRT): Combined estrogen and progesterone treatment for women who have reached or passed menopause.

Human immunodeficiency virus (HIV): The virus that causes AIDS.

Mammography: An x-ray of the breast used to identify suspicious or malignant tissue and locate the spread of cancer.

Menarche: The first menstrual period.

Menopause: The cessation of menstruation resulting from depletion of ovarian follicles and declining estrogen levels.

Oral contraceptives (OC): Birth control pills that provide supplemental hormone therapy and contraceptive benefit until a woman is postmenopausal.

Osteoporosis: Decreased density or thinning of the bone over time.

Papanicolaou (Pap) test: A test for the early detection of cervical cancer cells.

Perimenopause: The years preceding menopause when a woman can experience significant physical and emotional changes as she goes from a reproductive state to a postreproductive state. Perimenopause begins with the onset of menopausal symptoms and ends one year after the permanent cessation of menses. The terms female climacteric and "change of life" often are used to describe this time.

Postmenopause: The period of time after 12 consecutive months without any menstrual bleeding.

Premenstrual syndrome (PMS): A cluster of symptoms that occurs two to three days before the onset of menstruation, and lasting for the first few days of the menstrual period.

Sexually transmitted infection (STI): An infection acquired during sexual activity, usually during sexual intercourse with an infected individual.

Unopposed estrogen: This is a term applied to the administration of estrogen alone. Unopposed estrogen therapy should be used only in women who do not have a uterus. For women who have a uterus, unopposed estrogen therapy may cause endometrial hyperplasia, which can lead to endometrial cancer.

Works Cited

1. Cobb CM. Microbes, inflammation, scaling and root planning, and the periodontal condition. J Dent Hyg. 2008;82(suppl 3):4-9.

2. Merck Manuals Online. Periodontitis. Available at http://www.merckmanuals.com/home/mouth_and_dental_disorders/periodontal_diseases/periodontitis.html. Last accessed January 16, 2014.

3. Paquette DW, Ryan ME, Wilder RS. Locally delivered antimicrobials: clinical evidence and relevance. J Dent Hyg. 2008;82 (suppl 3):10-15.

4. Page RC, Offenbacher S, Schroeder HE, Seymour GJ, Kornman KS. Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontology. 1997;14:216-248.

5. U.S. Department of Health and Human Services. A Report of the Task Force on the NIH Women's Health Research Agenda for the 21st Century, Volume 1. Executive Summary. Bethesda, MD: National Institutes of Health; 1999.

6. U.S. Department of Health and Human Services. Oral Health in America: A Report of the Surgeon General. Available at http://www.nidcr.nih.gov/DataStatistics/SurgeonGeneral/sgr/home.htm. Last accessed January 16, 2014.

7. Academy of General Dentistry. Women's Oral Health Issues. Available at http://www.ada.org/sections/professionalresources/pdfs/healthcare_womens.pdf. Last accessed January 16, 2014.

8. Soikkonen K, Wolf J, Salo T, Tilvis R. Radiographic periodontal attachment loss as an indicator of death risk in the elderly.J Clin Periodontol. 2000;27(2):87-92.

9. Scannapieco FA, Research, Science and Therapy Committee of the American Academy of Periodontology. Position paper: periodontal disease as a potential risk factor for systemic diseases. J Periodontol. 1998;69(7):841-850.

10. Teng YT, Taylor GW, Scannapieco F, et al. Periodontal health and systemic disorders. J Can Dent Assoc. 2002;68(3)188-192.

11. Rose LF, Steinberg BJ, Minsk L. The relationship between periodontal disease and systemic conditions. Compend Contin Educ Dent. 2000;21(10A):870-877.

12. Anil S, Al-Ghamdi HS. The impact of periodontal infections on systemic disease: an update for medical practitioners. Saudi Med J. 2006;27(6):767-776.

13. Ford PJ, Raphael SL, Cullinan MP, Jenkins AJ, West MJ, Seymour GJ. Why should a doctor be interested in oral disease?Expert Rev Cardiovasc Ther. 2010;8(10):1483-1493.

14. Anderson SE, Must A. Interpreting the continued decline in the average age at menarche: results from two nationally representative surveys of U.S. girls studied 10 years apart. J Pediatr. 2005;147(6):753-760.

15. Weinberg MA. Women and Oral Health. Available at http://www.medscape.com/viewarticle/441902. Last accessed January 16, 2014.

16. HealthPartners Dental Group and Clinics. Guidelines for the Diagnosis and Treatment of Periodontal Diseases. Minneapolis, MN: HealthPartners; 2006.

17. American Dental Association Council on Access, Prevention, and Interprofessional Relations. Oral Health Care Series: Women's Oral Health Issues. Available at http://www.ada.org/sections/professionalResources/pdfs/healthcare_womens.pdf. Last accessed January 27, 2014.

18. Holder A, Edmundson LD. Dysmenorrhea. Available at http://emedicine.medscape.com/article/795677-overview. Last accessed January 27, 2014.

19. Moreno MA, Giesel AE, Rogers CB, Clark LR. Premenstrual Syndrome. Available at http://emedicine.medscape.com/article/953696-overview. Last accessed January 16, 2014.

20. Mashburn J. Etiology, diagnosis, and management of vaginitis. J Midwifery Womens Health. 2006;51(6):423-430.

21. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR. 2006;55(RR11): 1-100.

22. Youngkin EQ, Davis MS. Women's Health: A Primary Care Clinical Guide. 3rd ed. Stamford, CT: Appleton and Lange; 2003.

23. Chan PD, Johnson SM. Gynecology and Obstetrics. 9th ed. Laguna Hills, CA: Current Clinical Strategies; 2007.

24. Taber's Online. Available at http://www.tabers.com/tabersonline. Last accessed January 16, 2014.

25. Cottrell BH. Vaginal douching. J Obstet Gynecol Neonatal Nurs. 2003;32(1):12-18.

26. Mayo Clinic. Endometriosis. Available at http://www.mayoclinic.org/diseases-conditions/endometriosis/basics/definition/CON-20013968. Last accessed January 17, 2014.

27. Guo SW, Wang Y. The prevalence of endometriosis in women with chronic pelvic pain. Gynecol Obstet Invest. 2006;62:121-130.

28. Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc. 2001;41(6).

29. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA. 2000;281(1): 72-78.

30. Tanis BC. Oral contraceptives and the risk of myocardial infarction. Eur Heart J. 2003;24(5):377-380.

31. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(2):517-584.

32. Kennon S, Tasch EG, Arm RN. Considerations in the management of patients taking oral contraceptives. J Am Dent Assoc. 1978;97(4):641-643.

33. Jensen J, Liljemark W, Bloomquist C. The effect of female sex hormones on subgingival plaque. J Periodontol. 1981;52(10):599-602.

34. Magnusson T, Ericson T, Hugoson A. The effect of oral contraceptives on the concentration of some salivary substances in women. Arch Oral Biol. 1975;20(2):119-126.

35. El-Ashiry GM, El-Kafrawy AH, Nasr MF, Younis N. Effects of oral contraceptives on the gingiva. J Periodontol. 1971;42(5):273-275.

36. Rose LF, Kaye D (eds). Internal Medicine for Dentistry. 2nd ed. St. Louis, MO: Mosby; 1990.

37. Sweet JB, Butler DP. Increased incidence of postoperative localized osteitis in mandibular third molar surgery associated with patients using oral contraceptives. Am J Obstet Gynecol. 1977;127(5):518-519.

38. Castellini J, Harvey D, Erickson S, Cherkin D. Effect of oral contraceptive cycle on dry socket (localized alveolar osteitis).J Am Dent Assoc. 1980;101(5):777-780.

39. Brusca MI, Rosa A, Albaina O, Moragues MD, Verdugo F, Ponton J. The impact of oral contraceptives on women's periodontal health and the subgingival occurrence of aggressive periodontopathogens and Candida species. J Periodontol. 2010;81(7):1010-1018.

40. ADA Council on Scientific Affairs. Antibiotic interference with oral contraceptives. J Am Dent Assoc. 2002;133(7):880.

41. Burroughs KE, Chambliss ML. Antibiotics and oral contraceptive failure. Arch Fam Med. 2000;9:81-82.

42. Kornman KS, Loesche WJ. The subgingival microbial flora during pregnancy. J Periodont Res. 1980;15(2):111-122.

43. Carrillo-de-Albornoz A, Figuero E, Herrera D, Bascones-Martinez A. Gingival changes during pregnancy: II. Influence of hormonal variations on the subgingival biofilm. J Clin Periodontol. 2010;37(3):230-240.

44. Markou E, Eleana B, Lazaros T, Antonios K. The influence of sex steroid hormones on gingiva of women. Open Dent J. 2009;3: 114-119.

45. Lindhe J, Branemark PI. Changes in vascular permeability after local application of sex hormones. J Periodontol Res. 1967;2(4): 259-265.

46. Mariotti A. Sex steroid hormones and cell dynamics in the periodontium. Crit Rev Oral Biol Med. 1994;5(1):27-53.

47. Soory M. Targets for steroid hormone mediated actions of periodontal pathogens, cytokines and therapeutic agents: some implications on tissue turnover in the periodontium. Curr Drug Targets. 2000;1(4):309-325.

48. Miller LS, Manwell MA, Newbold D, et al. The relationship between reduction in periodontal inflammation and diabetes control: a report of nine cases. J Periodontol. 1992;63(10):843-848.

49. Shlossman M, Knowler WC, Pettitt DJ, Genco RJ. Type 2 diabetes mellitus and periodontal disease. J Am Dent Assoc. 1990;121(4):532-536.

50. Nagata T. Relationship between diabetes and periodontal disease. Clin Calcium. 2009;19(9):1291-1298.

51. Santos VR, Lima JA, De Mendonca AC, Braz Maximo MB, Faveri M, Duarte PM. Effectiveness of full-mouth and partial-mouth scaling and root planing in treating chronic periodontitis in subjects with type 2 diabetes. J Periodontol. 2009;80(8):1237-1245.

52. Jeffcoat MK, Geurs NC, Reddy MS, Cliver SP, Goldenberg RL, Hauth JC. Periodontal infection and preterm birth: results of a prospective study. J Am Dent Assoc. 2001;132(7):875-880.

53. Offenbacher S, Katz V, Fertik G, et al. Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol. 1996;67(10 suppl):1103-1113.

54. Jeffcoat MK, Geurs NC, Reddy MS, Goldenberg RL, Hauth JC. Current evidence regarding periodontal disease as a risk factor in preterm birth. Ann Periodontol. 2001;6(1):183-188.

55. López NJ, DaSilva I, Ipinza J, Gutiérrez J. Periodontal therapy reduces the rate of preterm low birth weight in women with pregnancy-associated gingivitis. J Periodontol. 2005;76(11):2144-2153.

56. American Academy of Periodontology. Gum Disease and Women. Available at http://www.perio.org/consumer/women.htm. Last accessed January 17, 2014.

57. Carta G, Persia G, Falciglia K, Iovenitti P. Periodontal disease and poor obstetrical outcome. Clin Exp Obstet Gynecol. 2004;31(1):47-49.

58. Offenbacher S, Jared HL, O'Reilly PG, et al. Potential pathogenic mechanisms of periodontitis associated pregnancy complications. Ann Periodontol. 1998;3(1):233-250.

59. Mitchell-Lewis D, Engebretson SP, Chen J, Lamster IB, Papapanou PN. Periodontal infections and pre-term birth: early findings from a cohort of young minority women in New York. Eur J Oral Sci. 2001;109(1):34-39.

60. ACOG Committee on Practice Bulletins Obstetrics. ACOG practice bulletin: management of preterm labor. Int J Gynaecol Obstet. 2003;82(1):127-135.

61. Dasanayake AP. Poor periodontal health of the pregnant woman as a risk factor for low birth weight. Ann Periodontol. 1998;3(1):206-212.

62. Khader YS, Ta'ani Q. Periodontal diseases and the risk of preterm birth and low birth weight: a meta-analysis. J Periodontol. 2005;76(2):161-165.

63. Lopez NJ, Da Silva I, Ipinza J, Gutierrez J. Periodontal therapy reduces the rate of preterm low birth weight in women with pregnancy-associated gingivitis. J Periodontol. 2005;76(11 suppl):2144-2153.

64. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2007;12(1):20-37.

65. Allen KM, Phillips JM. Women's Health Across the Lifespan: A Comprehensive Perspective. Philadelphia, PA: Lippincott, Williams and Wilkins; 1997.

66. Berman NR. Human papillomavirus and cervical cancer screening: recent advances improve the clinical picture. Adv Nurse Pract. 2002;10(10):26-35.

67. National Cancer Institute. Cervical Cancer. Available at http://www.cancer.gov/cancertopics/types/cervical. Last accessed January 21, 2014.

68. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.CACancer J Clin. 2012;62(3):147-172.

69. Centers for Disease Control and Prevention. Cervical Cancer Screening Guidelines for Average-Risk Women. Available at http://www.cdc.gov/cancer/cervical/pdf/guidelines.pdf. Last accessed January 21, 2014.

70. U.S. Preventive Services Task Force. Screening for Cervical Cancer. Available at http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancersum.pdf. Last accessed January 21, 2014.

71. U.S. Food and Drug Administration. FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108666.htm. Last accessed January 23, 2014.

72. U.S. Food and Drug Administration. Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant. Available at http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM094042. Last accessed January 23, 2014.

73. American Cancer Society. Treating Cervical Cancer: About Treatment. Available at http://www.cancer.org/Cancer/CervicalCancer/OverviewGuide/cervical-cancer-overview-treating-general-info. Last accessed January 23, 2014.

74. American Cancer Society. Endometrial (Uterine) Cancer. Available at http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-key-statistics. Last accessed January 23, 2014.

75. Banno K, Susumu N, Yanokura M, et al. Association of HNPCC and endometrial cancers. Int J Clin Oncol. 2004;9(4):262-269.

76. Carlson K, Eisenstat S, Frigoletto F, Schiff I. Primary Care of Women. St. Louis, MO: Mosby; 2002.

77. American Cancer Society. Ovarian Cancer: Detailed Guide. Available at http://www.cancer.org/cancer/ovariancancer/detailedguide/index. Last accessed January 23, 2014.

78. National Cancer Institute. Factsheet: Probability of Breast Cancer in American Women. Available at http://www.cancer.gov/cancertopics/factsheet/detection/probability-breast-cancer. Last accessed January 23, 2014.

79. American Cancer Society. Breast Cancer: Detailed Guide. Available at http://www.cancer.org/cancer/breastcancer/detailedguide/index. Last accessed January 23, 2014.

80. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005;143(5):355-361.

81. National Cancer Institute. Breast Cancer Screening: Overview. Available at http://www.cancer.gov/cancertopics/pdq/screening/breast/healthprofessional#Section_33. Last accessed January 23, 2014.

82. American Cancer Society. Can Breast Cancer Be Found Early? Available at http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-detection. Last accessed January 23, 2014.

83. National Cancer Institute. Breast Cancer Screening Modalities–Mammography. Available at http://www.cancer.gov/cancertopics/pdq/screening/breast/HealthProfessional/page5. Last accessed January 27, 2014.

84. National Cancer Institute. SEER Stat Fact Sheets: Breast Cancer. Available at http://seer.cancer.gov/statfacts/html/breast.html. Last accessed January 27, 2014.

85. American Heart Association. Suggested Servings from Each Food Group. Available at http://www.heart.org/HEARTORG/GettingHealthy/NutritionCenter/HealthyDietGoals/Suggested-Servings-from-Each-Food-Group_UCM_318186_Article.jsp. Last accessed January 27, 2014.

86. National Cancer Institute. Stage Information for Breast Cancer. Available at http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page4. Last accessed January 27, 2014.

87. Chan PD, Johnson SM. Gynecology and Obstetrics. 9th ed. Laguna Hills, CA: Current Clinical Strategies; 2007.

88. Zachariasen RD. Oral manifestations of menopause. Compendium. 1993;14(12):1584-1591.

89. Youngkin EQ, Davis MS. Women's Health: A Primary Care Clinical Guide. 3rd ed. Stamford, CT: Appleton & Lange; 2003.

90. Mayo Clinic. Menopause. Available at http://www.mayoclinic.org/diseases-conditions/menopause/basics/definition/CON-20019726. Last accessed January 27, 2014.

91. George SA. The menopause experience: a woman's perspective. J Obstet Gynecol Neonatal Nurs. 2006;31(1):77-85.

92. Ferguson MM, Carter J, Boyle P, Hart DM, Lindsay R. Oral complaints related to climacteric symptoms in oophorectomized women. J R SocMed. 1981;74(7):492-498.

93. American Heart Association. Available at American Heart Association Recommendations for Physical Activity in Adults. http://www.heart.org/HEARTORG/GettingHealthy/PhysicalActivity/StartWalking/American-Heart-Association-Recommendations-for-Physical-Activity-in-Adults_UCM_307976_Article.jsp. Last accessed January 27, 2014.

94. Friedlander AH. The physiology, medical management and oral implications of menopause. J Am Dent Assoc. 2002;133(1):73-81.

95. Frutos R, Rodriguez S, Miralles-Jorda L. Machuca G. Oral manifestations and dental treatment in menopause. Med Oral. 2002;7(1):26-30, 31-35.

96. Meurman JH, Tarkkila L, Tiitinen A. The menopause and oral health. Maturitas. 2009;63(1):56-62.

97. American Academy of Periodontology. Women and Gum Disease: Your Unique Oral Health Needs. Chicago, IL: American Academy of Periodontology; 1993.

98. Frackiewicz EJ, Cutler NR. Women's health care during the perimenopause. J Am Pharm Assoc. 2000;40(6).

99. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33.

100. Women's Health Initiative. Available at http://www.nhlbi.nih.gov/whi. Last accessed January 27, 2014.

101. Bruckner MC, Youngkin EO. What's a woman to do? Exploring HRT questions raised by the women's health initiative.Nurs Womens Health. 2002;6(5):408-417.

102. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.

103. Maxson J. Remedying dyslipidemia: NCEP-ATP III strategies to slow CVD. Clin Rev. 2002;12(10):53-60.

104. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325(11):756-762.

105. Gabriel Sanchez R, Sanchez Gomez LM, Carmona L, Roque I Figuls M, Bonfill Cosp X. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2005;2:CD002229.

106. American Cancer Society. Menopausal Hormone Replacement Therapy and Cancer Risk. Available at http://www.cancer.org/cancer/cancercauses/othercarcinogens/medicaltreatments/menopausal-hormone-replacement-therapy-and-cancer-risk. Last accessed January 27, 2014.

107. Richards SS, Hendrie HC. Diagnosis, management and treatment of Alzheimer's disease: a guide for the internist. Arch Intern Med. 1999;159(8):789-798.

108. Brinton RD. A women's health issue: Alzheimer's disease and strategies for maintaining cognitive health. Int J Fertil Womens Med. 1999;44(4):174-185.

109. Manly JJ, Merchant CA, Jacobs DM, et al. Endogenous estrogen levels and Alzheimer's disease among post menopausal women. Neurology. 2000;54(4):833-837.

110. Hogervorst E, Yaffe K, Richards M, Huppert FA. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev. 2009;21(1):CD003799.

111. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev. 2008;23(1):CD003122.

112. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteoporosis. Available at http://www.niams.nih.gov. Last accessed January 27, 2014.

113. Wactawski-Wende J. Periodontal diseases and osteoporosis: association and mechanisms. Ann Periodontol. 2001;6(1):197-208.

114. Grodstein F, Colditz GA, Stampfer MJ. Post-menopausal hormone use and tooth loss: a prospective study. J Am Dent Assoc. 1996;127(3):370-377.

115. Mohammad AR, Brunsvold M, Bauer R. The strength of association between systemic postmenopausal osteoporosis and periodontal disease. Int J Prosthodont. 1996;9(5):479-483.

116. Kribbs PJ. Comparison of mandibular bone in normal and osteoporotic women. J Prosthet Dent. 1990;63(2):218-222.

117. von Wowern N, Klausen B, Kollerup G. Osteoporosis: a risk factor in periodontal disease. J Periodontol. 1994;65(12):1134-1138.

118. Weyant RJ, Pearlstein ME, Churak AP, Famili P, Cauley JA. The association between osteopenia and periodontal attachment loss in older women. J Periodontol. 1999;70(9):982-991.

119. Paganini-Hill A. The benefits of estrogen replacement therapy on oral health: the Leisure World Cohort. Arch Intern Med. 1995;155(21):2325-2329.

120. Jeffcoat MK, Reddy MS. Alveolar bone loss and osteoporosis: evidence for a common mode of therapy using the bisphosphonate alendronate. In: Davidovitch Z (ed). The Biologic Mechanism of Tooth Eruption, Resorption and Replacement by Implants. Boston, MA: Harvard Society for the Advancement of Orthodontics; 1998.

121. Giannobile WV. Host-response therapeutics for periodontal diseases. J Periodontol. 2008;79(8 suppl):1592-1600.

122. Takaishi Y, Miki T, Nishizawa Y, Morii H. Clinical effect of etidronate on alveolar pyorrhoea associated with chronic marginal periodontitis: report of four cases. J Int Med Res. 2001;29:355-365.

123. Rocha M, Nava LE, Vázquez de la Torre C, Sánchez-Marin F, Garay-Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial. J Periodontol. 2001;72:204-209.

124. Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc. 2006;81(5):662-672.

125. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause. 2010;17(1):25-54.

126. Gamble CL. Osteoporosis: drug and nondrug therapies for the patient at risk. Geriatrics. 1995;50(8):39-43.

127. LexiComp Online. Available at http://online.lexi.com. Last accessed January 27, 2014.

128. Moore A. Menopausal health strategies: focus on osteoporosis. Am J Nurse Pract. 2003;7(2):9-21.

129. Office on Women's Health. Osteoporosis. Available at http://www.womenshealth.gov/aging/diseases-conditions/osteoporosis.html. Last accessed January 27, 2014.

130. American Heart Association. Heart Disease and Stroke Statistics: Update 2013. Available at http://circ.ahajournals.org/content/127/1/e6.full.pdf+html. Last accessed January 27, 2014.

131. American Heart Association. Heart Attack Symptoms in Women. Available at http://www.heart.org/HEARTORG/Conditions/HeartAttack/WarningSignsofaHeartAttack/Heart-Attack-Symptoms-in-Women_UCM_436448_Article.jsp. Last accessed January 27, 2014.

132. American Heart Association. Menopause and Heart Disease. Available at http://www.heart.org/HEARTORG/Conditions/More/MyHeartandStrokeNews/Menopause-and-Heart-Disease_UCM_448432_Article.jsp. Last accessed January 27, 2014.

133. Office on Women's Health. Heart Health and Stroke. Available at http://womenshealth.gov/heart-health-stroke/index.html. Last accessed January 27, 2014.

134. Mattila KJ, Nieminen MS, Valtonen VV, et al. Association between dental health and acute myocardial infarction. BMJ. 1989;298(6676):779-781.

135. Mattila KJ, Valle MS, Nieminen MS, et al. Dental infections and coronary atherosclerosis. Atherosclerosis. 1993;103(2):205-211.

136. Willershausen B, Kasaj A, Willershausen I, et al. Association between chronic dental infection and acute myocardial infarction.J Endod. 2009;35(5):626-630.

137. Kaisare S, Rao J, Dubashi N. Periodontal disease as a risk factor for acute myocardial infarction: a case-control study in Goans highlighting a review of the literature. Br Dent J. 2007;203(3):E5.

138. Stein JM, Kuch B, Conrads G, et al. Clinical periodontal and microbiologic parameters in patients with acute myocardial infarction. J Periodontol. 2009;80(10):1581-1589.

139. DeStefano F, Anda RF, Kahn HS, Williamson DF, Russell CM. Dental disease and risk of coronary heart disease and mortality. BMJ. 1993;306(6879):688-691.

140. Suzuki J, Aoyama N, Ogawa M, et al. Periodontitis and cardiovascular disease. Expert Opin Ther Targets. 2010;13(10:1023-1027.

141. Krejci CB, Bissada NF. Women's health issues and their relationship to periodontitis. J Am Dent Assoc. 2002;133(2):323-329.

142. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques.J Periodontol. 2000;71(10):1554-1560.

143. Demmer RT, Desvarieux M. Periodontal infections and cardiovascular disease: the heart of the matter. J Am Dent Assoc. 2006;137 (suppl):14S-20S.

144. Shafer WG, Hine MK, Levy WM. A Textbook of Oral Pathology. 4th ed. Philadelphia, PA: WB Saunders Co.; 2003.

145. Centers for Disease Control and Prevention. Sexually Transmitted Diseases (STDs). Available at http://www.cdc.gov/std/default.htm. Last accessed January 27, 2014.

146. Workowski KA, Berman S, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR. 2010;59(RR-12):1-110.

147. Bobak I, Lowdermilk D, Jensen M. Maternity and Gynecologic Care: The Nurse and the Family. 5th ed. St. Louis, MO: Mosby; 1997.

148. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organizations' global strategy for prevention and assessment of HIV drug resistance. Antiviral Therapy. 2008;13(suppl 2):1-13.

149. Lifante-Olivia C, Lopez-Jornet P. Camacho-Alonson F, Esteve-Salinas J. Study of oral changes in patients with eating disorders.Int J Dent Hyg. 2008;6(2):119-122.

150. Brown S, Bonifazi DZ. An overview of anorexia and bulimia nervosa and the impact of eating disorders on the oral cavity. Compendium. 1993;14(12):1594-1608.

151. Austin SB, Ziyadeh NJ, Forman S, Prokop LA, Keliher A, Jacobs D. Screening high school students for eating disorders: results of a national initiative. Prev Chronic Dis. 2008;5(4).

152. DeBate RD, Tedesco LA, Kerschbaum WE. Knowledge of oral and physical manifestations of anorexia and bulimia nervosa among dentist and dental hygienists. J Dent Educ. 2005;69(3):346-354.

153. Mandel L, Kayna A. Bulimia and parotid swelling: a review and case report. J Oral Maxillofac Surg. 1992;50(10):1122-1125.

154. Ruff JC, Koch MO, Perkins S. Bulimia: dentomedical complications. Gen Dent. 1992;40(1):22-25.

155. Lo Russo L, Campisi G, De Fede O, Di Liberto C, Panzarella V, Lo Muzio L. Oral manifestations of eating disorders: a critical review. Oral Dis. 2008;14(6):479-484.

156. 156 . Council on Scientific Affairs American Medical Association. Violence against women: relevance for medical practitioners. JAMA. 1992;267(33):3184-3189.

157. Shipway L. Domestic Violence: A Handbook for Health Professionals. New York, NY: Routledge; 2004.

158. World Health Organization. Violence Against Women. Available at http://www.who.int/mediacentre/factsheets/fs239/en/index.html. Last accessed January 28, 2014.

159. Scherer D. Tort remedies for victims of domestic abuse. South Carolina Law Rev. 1992;43:543-579.

160. American Psychiatric Association. Domestic Violence. Available at http://www.healthyminds.org/Main-Topic/Domestic-Violence.aspx. Last accessed January 28, 2014.

161. Centers for Disease Control and Prevention. Intimate Partner Violence: Risk and Protective Factors. Available at http://www.cdc.gov/violenceprevention/intimatepartnerviolence/riskprotectivefactors.html. Last accessed January 28, 2014.

162. Futures Without Violence. National Consensus Guidelines on Identifying and Responding to Domestic Violence Victimization in Health Care Settings. Available at www.futureswithoutviolence.org/userfiles/file/Consensus.pdf. Last accessed January 28, 2014.

163. McLeer SV, Anwar RA. The role of the emergency physician in the prevention of domestic violence. Ann Emerg Med. 1987;16(10):1155-1161.

164. Chez RA, Jones RF. The battered woman. Am J Obstet Gynecol. 1995;173(3):677-679.

165. Horton AL, Boggess KA, Moss KL, Jared HL, Beck J, Offenbacher S. Periodontal disease early in pregnancy is associated with maternal systemic inflammation among African American women. J Periodontol. 2008;79(7):1127-1132.

166. Pitiphat W, Gillman MW, Joshipura KJ, Williams PL, Douglass CW, Rich-Edwards JW. Plasma C-reactive protein in early pregnancy and preterm delivery. Am J Epidemiol. 2005;162(11):1108-1113.

167. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR. 2010;59(20):626-629.

168. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin. 2009;5(10):705-719.

169. Centers for Disease Control and Prevention. HPV Vaccine Information for Young Women: Fact Sheet. Available at http://www.cdc.gov/std/hpv/stdfact-hpv-vaccine-young-women.htm. Last accessed January 23, 2014.

170. American College of Obstetricians-Gynecologists. Practice bulletin no. 122: breast cancer screening. Obstet Gynecol. 2011;118 (2 Pt 1):372-382.

171. Yackzan SG, Hatch J. Surgical management and reconstruction. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburg, PA: Oncology Nursing Society; 2011: 79-92.

172. Taghian A, El-Ghamry MN, Merajver SD. Inflammatory Breast Cancer: Clinical Features and Treatment. Available at http://www.uptodate.com/contents/inflammatory-breast-cancer-clinical-features-and-treatment. Last accessed January 27, 2014.

173. Moyer VA, U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;158(1):47-54.

174. Dodd DZ, Rowe DJ. The relationship between postmenopausal osteoporosis and periodontal disease. J Dent Hyg. 2013;87(6): 336-344.

175. American Association of Oral and Maxillofacial Surgeons. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ). Available at http://www.aaoms.org/conditions-and-treatments/bronj/. Last accessed January 27, 2014.

176. Anil S, Preethanath RS, AlMoharib HS, Kamath KP, Anand PS. Impact of osteoporosis and its treatment on oral health. Am J Med Sci. 2013;346(5):396-401.

177. Daily Med. Denosumab. Available at http://dailymed.nlm.nih.gov/dailymed/about.cfm. Last accessed January 27, 2014.

178. National Cancer Institute. FDA Approval for Denosumab. Available at http://www.cancer.gov/cancertopics/druginfo/fda-denosumab. Last accessed January 27, 2014.

179. McClung M. Role of RANKL inhibition in osteoporosis. Arthritis Res Ther. 2007;9(suppl 1):S3.

180. University of Maryland Medical Center. Herpes Simplex Virus. Available at http://umm.edu/health/medical/altmed/condition/herpes-simplex-virus. Last accessed January 27, 2014.

181. Thies W, Bleiler L, Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 2013;9(2):208-245.

182. Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR. 2012;61(31):590-594.

183. U.S. Food and Drug Administration. FDA Approves Gardasil 9 for Prevention of Certain Cancers Caused by Five Additional Types of HPV. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm. Last accessed January 8, 2015.

Evidence-Based Practice Recommendations Citations

1. U.S. Preventive Services Task Force. Screening for Osteoporosis. Available at http://www.uspreventiveservicestaskforce.org/uspstf/uspsoste.htm. Last accessed January 31, 2014.

2. American Academy of Periodontology. Comprehensive periodontal therapy: a statement by the American Academy of Periodontology. J Periodontol. 2011;82(7):943-949. Summary retrieved from National Guideline Clearinghouse at http://www.guideline.gov/content.aspx?id=34760. Last accessed January 31, 2014.

3. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Eating Disorders. 3rd ed. Washington, DC: American Psychiatric Association; 2006. Summary retrieved from National Guideline Clearinghouse at http://www.guideline.gov/content.aspx?id=9318. Last accessed January 31, 2014.

Copyright © 2014 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.